



# A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects

Elsie M. Sunderland<sup>1,2</sup> · Xindi C. Hu<sup>1,2</sup> · Clifton Dassuncao<sup>1,2</sup> · Andrea K. Tokranov<sup>2</sup> · Charlotte C. Wagner<sup>2</sup> · Joseph G. Allen<sup>1</sup>

Received: 6 September 2018 / Revised: 15 October 2018 / Accepted: 19 October 2018  
© Springer Nature America, Inc. 2018

## Abstract

Here, we review present understanding of sources and trends in human exposure to poly- and perfluoroalkyl substances (PFASs) and epidemiologic evidence for impacts on cancer, immune function, metabolic outcomes, and neurodevelopment. More than 4000 PFASs have been manufactured by humans and hundreds have been detected in environmental samples. Direct exposures due to use in products can be quickly phased out by shifts in chemical production but exposures driven by PFAS accumulation in the ocean and marine food chains and contamination of groundwater persist over long timescales. Serum concentrations of legacy PFASs in humans are declining globally but total exposures to newer PFASs and precursor compounds have not been well characterized. Human exposures to legacy PFASs from seafood and drinking water are stable or increasing in many regions, suggesting observed declines reflect phase-outs in legacy PFAS use in consumer products. Many regions globally are continuing to discover PFAS contaminated sites from aqueous film forming foam (AFFF) use, particularly next to airports and military bases. Exposures from food packaging and indoor environments are uncertain due to a rapidly changing chemical landscape where legacy PFASs have been replaced by diverse precursors and custom molecules that are difficult to detect. Multiple studies find significant associations between PFAS exposure and adverse immune outcomes in children. Dyslipidemia is the strongest metabolic outcome associated with PFAS exposure. Evidence for cancer is limited to manufacturing locations with extremely high exposures and insufficient data are available to characterize impacts of PFAS exposures on neurodevelopment. Preliminary evidence suggests significant health effects associated with exposures to emerging PFASs. Lessons learned from legacy PFASs indicate that limited data should not be used as a justification to delay risk mitigation actions for replacement PFASs.

## Introduction

Poly- and perfluoroalkyl substances (PFASs) are a family of more than 4000 highly fluorinated aliphatic compounds manufactured for diverse applications [1]. They have been

widely used for their hydrophobic and oleophobic properties in consumer products such as disposable food packaging, cookware, outdoor gear, furniture, and carpet. They are also one of the main components (1–5% w/w) [2] of aqueous film forming foams (AFFF) used frequently at airports and military bases for firefighting and training activities [3]. AFFF contamination of groundwater is a major source of drinking water contamination and has been identified as a nationally significant challenge in countries such as the US and Sweden [4, 5]. Releases of PFASs to the environment can occur next to chemical manufacturing locations, at industrial sites where PFASs are used, and at various stages of product use and disposal. The carbon–fluorine bond in these compounds is extremely strong and thus many PFASs are not appreciably degraded under environmental conditions

---

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1038/s41370-018-0094-1>) contains supplementary material, which is available to authorized users.

---

✉ Elsie M. Sunderland  
ems@seas.harvard.edu

<sup>1</sup> Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>2</sup> Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA, USA

[6]. This has resulted in their accumulation in the environment since the onset of production in the late 1940s [7].

International concern regarding potential health effects associated with PFAS exposure began in the early 2000s when perfluorooctanesulfonate (PFOS) was detected in the blood of polar bears in the Arctic and wildlife in other remote regions [8]. Early data on PFOS bioaccumulation in aquatic food webs indicated the propensity for human exposure to these compounds through seafood [9]. The U.S. Centers for Disease Control and Prevention (CDC) later reported these compounds are detectable in the blood of virtually all Americans (98%) [10–12]. Between 2000 and 2002, the main global manufacturer of PFASs (3M) voluntarily discontinued manufacturing of the parent chemical used to produce PFOS and its precursors [13]. The US introduced a variety of programs to curb the use of the most abundant environmental PFASs, including the PFOA Stewardship Program enacted in 2006 to end production of the longest chained compounds by 2015. PFOS was added to the Stockholm Convention's list of globally restricted Persistent Organic Pollutants (POPs) in 2009.

Human exposures to PFOS and PFOA have been declining in western countries and Japan over the last decade [14–16] due to these regulatory interventions while understanding of their adverse effects on human health has been rapidly advancing [17]. At the same time, a proliferation of new PFASs has been reported in the environmental literature as the industry has rapidly replaced PFOS and PFOA with shorter chain length PFASs and new chemicals that are difficult to detect using standard methods [3]. Emerging evidence from animal experiments suggests some of these alternative PFASs can be equally hazardous [18]. Environmental health scientists thus face a considerable challenge in understanding the relative importance of diverse exposure pathways to PFASs in different human populations and their potential effects on human health in a rapidly changing chemical landscape.

Here we review current understanding of: (1) the predominant exposure pathways for PFASs for different populations, (2) health impacts associated with exposure, and (3) critical research needs for the future. We focus on four health effects: cancer, immune effects, metabolic effects, and neurodevelopment. We use this review to summarize key knowledge gaps and future research needs.

## PFAS nomenclature

All PFASs contain at least one perfluoroalkyl moiety ( $C_nF_{2n+1}$ ) [19]. Fully fluorinated aliphatic carbon chains are known as perfluoroalkyl substances while those with the incomplete replacement of hydrogen atoms by fluorine are referred to as polyfluoroalkyl substances. Perfluoroalkyl

acids (PFAAs) include perfluoroalkyl carboxylic, sulfonic, phosphonic, and phosphinic acids, which are differentiated by their functional groups. Most research has focused on perfluoroalkyl carboxylic acids (PFCAs) and perfluoroalkyl sulfonic acids (PFSAs) with between four and sixteen (C4–C16) carbons. Long-chain PFASs are defined as PFCAs with seven or more perfluorinated carbons and PFSAs with six or more perfluorinated carbons. The fluorinated carbon chain of these chemicals is both hydrophobic and oleophobic but the head group for many PFASs is easily deprotonated, resulting in high stability in solution. High water solubility of some PFASs has led to their accumulation in groundwater, rivers, and the ocean and contamination of drinking water resources, fish and marine mammals.

PFAA precursors, hereon referred to as “precursors”, are compounds that can biotically, and sometimes abiotically, degrade to PFAAs [6, 20]. Volatile precursors can be transported long distances in the atmosphere prior to deposition in regions remote from pollution sources [21, 22]. Precursors are often not measured during standard PFAA analysis, which can result in an underestimate of human exposure because they can be metabolized to terminal PFAAs in the human body [23, 24].


## Human exposure pathways

Figure 1 provides an overview of the pathways for human exposure to PFASs. Human exposure to PFASs occurs through ingestion of contaminated drinking water and seafood, inhalation of indoor air, and contact with other contaminated media [25]. PFASs are often used for their “non-stick” and surface-tension lowering properties, which makes them useful for repelling oil and water (preventing stains) and modifying surface chemistry. The latter includes applications such as AFFF, processing aids for fluoropolymer manufacture, metal plating, and the production of semiconductors [26, 27]. Direct exposures due to use in products can be quickly phased out by shifts in chemical production but exposures driven by PFAS accumulation in the ocean and marine food chains and AFFF contamination of groundwater persist over long timescales [28, 29]. Understanding the relative importance of these different exposure pathways is thus critical for interpreting drivers of temporal differences in serum PFAS concentrations measured in biomonitoring studies [28, 30], and for anticipating future exposure risks.

## Consumer products, indoor air, and dust

PFASs have been detected in jackets, upholstery, carpets, papers, building materials, food contact materials, impregnation agents, cleansers, polishes, paints, and ski waxes,

**Fig. 1** Overview of PFAS exposure pathways for different human populations outside of occupational settings



among many other items commonly found in offices, households, and cars [31–40]. PFASs can migrate from fluorochemical-treated food contact papers into food-simulants such as butter, water, vinegar, and water/ethanol mixtures, indicating a direct exposure route to humans [36, 41, 42]. Dermal exposure to PFOS and PFOA from products is thought to be low [25]. In a study of 41 Norwegian women, Haug et al. [23] reported that food is typically the dominant exposure pathway, although the indoor environment (dust, air) could account for up to ~50% of the total PFAS intake.


Precursor compounds in many consumer products can be biotransformed in the human body to PFAAs, leading to additional uncertainty regarding the significance of exposures from this source [23, 24]. Inhalation of volatile precursors is known to occur and these precursors have been measured in indoor environments where PFAS containing products are used [43, 44]. The phase-out of PFOS and PFOA and their precursors has led to the increased production of short-chain compounds and structurally similar alternative compounds [3, 6], requiring a more holistic approach to determining human exposure from fluorinated compounds. To address this challenge, Robel et al. [32] measured total fluorine concentrations and determined the fraction of fluorine that can migrate from a select group of consumer products and is available for human exposure. The authors reported that typical measurement techniques for PFASs only account for up to 16% of the total fluorine measured using particle-induced gamma ray emission (PIGE) [32]. Additional research is thus needed to establish the link between the PFAS concentrations in products and the concentrations in dust, air, and food and their overall

contributions to human exposure in populations with diverse product use patterns.

### Drinking water

Drinking water has been identified as a substantial source of PFAS exposure for many populations, particularly those living near contaminated sites [4, 5]. The United States Environmental Protection Agency (U.S. EPA) proposed a lifetime health advisory level for PFOS+PFOA of 70 ng/L in drinking water in 2016 [45]. In 2018, the Agency for Toxic Substances and Disease Registry (ATSDR) in the US further lowered the Minimum Risk Levels (MRLs) for PFOS and PFOA by approximately an order of magnitude compared to the reference dose (RfD) used by the U.S. EPA to develop the 2016 lifetime advisory [46]. Drinking water advisory levels corresponding to the MRLs used by ATSDR would be 11 ng/L for PFOA and 7 ng/L for PFOS. Some lifetime drinking water advisories proposed by other state and international agencies include up to 11 or 12 PFASs (Sweden and Denmark) and range from less than 10 ng/L up to hundreds to thousands of ng/L for different PFASs in Canada [47]. Notably, Grandjean and Budtz-Jørgensen [48] estimated the lifetime drinking water advisory level should be less than 1 ng/L based on the benchmark dose for immunotoxicity associated with PFAS exposure for children in the Faroe Islands.

Figure 2 shows the growth in the identification of sites contaminated by PFASs across the US between 1999 and 2017. PFAS contamination of drinking water was first reported in the US in public and private drinking water supplies near a fluoropolymer manufacturing facility in Washington, WV in 1999 [49]. The average PFOA



**Fig. 2** Discovery of sites contaminated by PFASs leading to elevated concentrations in drinking water across the US. Figure adapted from data compiled by Northeastern University's Social Science

Environmental Health Research Institute (SSEHRI) that was last updated 12/17/17 [162]. Colors of circles represent different types of pollution source, and magnitudes indicate sizes of local communities

concentration of in one public water supply, the Little Hocking water system, was  $3550 \text{ ng L}^{-1}$  (range  $1500\text{--}7200 \text{ ng L}^{-1}$ ) between 2002 and 2005. Drinking water contamination near a military base was first discovered in Michigan in 2010. Many additional cases of high concentrations of PFASs in finished drinking water across the US have since been reported (Fig. 2).

Most of these cases focus on single communities or small areas with a known point source of contamination. The first statewide study of PFAS occurrence in the US drinking water was conducted by New Jersey, where PFOA was detected in 59% of the public water supplies and maximum concentrations reached  $190 \text{ ng L}^{-1}$  [50]. The first nationwide occurrence survey of PFASs in public water supplies was conducted between 2013 and 2015 by the U.S. EPA under the third Unregulated Contaminant Monitoring Rule (UMCR3) [51]. Hu et al. [4] noted that drinking water concentrations of PFOS and/or PFOA exceeding the U.S. EPA 2016 health advisory levels were detected in large public water supplies serving approximately six million Americans. Further, there are no data for approximately 100

million Americans who obtain their water from small public water supplies serving less than 10,000 individuals and private wells, representing a critical research need for the future.

Following the shift in PFAS production away from PFOS, PFOA and their precursors, different PFASs may now be accumulating in drinking water and become relevant for human exposure. Newer PFASs, such as GenX, have been detected at high concentration (hundreds of  $\text{ng L}^{-1}$ ) in the Cape Fear River watershed in North Carolina, downstream of a PFAS manufacturing plant [52]. The large-scale implications of such findings have yet to be evaluated and knowledge of the international significance of drinking water contamination by PFASs continues to advance at a rapid pace.

### Seafood

Elevated serum concentrations of PFASs have been reported for a number of seafood consuming populations, including Inuit men in Greenland who frequently consume


seafood and marine mammals [53], whaling men in the Faroe Islands [54], and commercial fishery employees in China [55]. Seafood PFAS concentrations vary considerably with highest concentrations measured next to contaminated sites [56, 57]. Environmental concentrations of long-chain compounds appear to be the main driver of variability in tissue concentrations across sites and species [56, 58, 59]. Long-chained compounds and PFASs bioaccumulate to a greater degree than shorter chain length compounds and PFCAs [60, 61]. However, early studies of bioaccumulation potential were based on assays designed for highly lipophilic substances and therefore do not provide comprehensive information on all PFASs presently in use [58].

There is considerable variability in the contribution of seafood to the overall exposure of humans to PFASs. Cooking has been shown to reduce concentrations of some PFASs such as PFOS [59]. Christensen et al. [62] found higher concentrations of serum PFASs among high-frequency fish consumers in the U.S. National Health and Nutrition Exam Survey between 2007 and 2014. The European Food Safety Authority (EFSA) recently estimated that “fish and other seafood” account for up to 86% of dietary PFAS exposure in adults [57]. Hu et al. [63] showed that the presence of elevated serum concentrations of PFASs with  $C \geq 9$  chain-length in humans is useful for identifying when seafood is a dominant exposure source. Birth cohort data from the Faroe Islands confirmed this observation by showing strong associations between serum concentrations of perfluoroundecanoic acid (PFUnDA, C11) and hair mercury concentrations, which are a strong tracer of seafood consumption [30]. Concentrations of legacy PFASs in marine biota have lagged shifts in production away from these compounds, resulting in increased significance of seafood as an exposure source [30].

### Biosolids and agriculture

Many PFASs used in products or in industry enter the waste stream and are channeled to wastewater treatment plants. Wastewater treatment plants themselves are thus point sources for PFAS pollution [57]. The presence of greater than three treatment plants within a catchment has been associated with increased likelihood of PFAS detection in drinking water [4]. Data on the full suite of PFASs present in wastewater plumes are limited and this is expected to change temporally as chemical production and use in products shifts.

Figure 3 shows temporal changes in catchment level discharges of PFOS from wastewater treatment plants across the US between 1995 and 2005 [29]. PFOS discharges were modeled based on wastewater flow rates ( $m^3 \text{ day}^{-1}$ ) from the Clean Watersheds Needs Survey (CWNS)



**Fig. 3** PFOS discharges from wastewater treatment plants into streams and rivers across the US in 1995 and 2005. Adapted from data presented in Zhang et al. [29] and PFOS production estimates Wang et al. [166]

2008 Report to Congress and an empirical relationship between population served by wastewater treatment plants and PFOS concentrations, as described in Zhang et al. [29]. Higher levels of PFOS discharges from wastewater treatment plants are apparent in 1995 prior to the phase-out between 2000 and 2002 [26, 29]. Discharges from wastewater enter regional river networks and ultimately result in large inputs to marine ecosystems as the terminal sink. For PFOS, wastewater was thought to account for approximately 85% of releases on a continental scale, while industrial sites can be most significant at the local scale [64, 65].

Sewage sludge from wastewater treatment plants is often used for fertilizer in agriculture, presenting another potential vector for human exposure. Several studies have detected PFASs in such biosolids [66–68]. The 2001 U.S. EPA National Sewage Sludge Survey suggested that the load of PFASs in the US biosolids was  $2749\text{--}3450 \text{ kg year}^{-1}$  based on the 13 PFASs measured. Of this total US load, an estimated  $1375\text{--}2070 \text{ kg year}^{-1}$  was applied for agriculture and

467–587 kg year<sup>-1</sup> was transported to landfills [68]. Several studies have also investigated the uptake of PFASs into crops and earthworms from biosolids application [69–71]. In one study, concentration factors for roots relative to soil up to 4.7 and 10.3 were found for PFOS and PFOA, respectively, and all seven plants investigated displayed root concentration factors greater than one [71]. Elevated PFAS concentrations in meat and dairy products have also been reported [57, 72], suggesting PFAS uptake from biosolids contaminated agriculture is a source of dietary exposure for farm animals. Additional research on the significance of human exposures to PFASs originating from biosolids and agriculture is needed.

## Approaches for quantifying exposure sources

Table 1 presents some literature estimates of source contributions to overall PFAS exposures for adults. There is general agreement that dietary intake is the largest source of PFAS exposure rather than inhalation or dermal contact. However, the relative importance of different source categories varies dramatically across demographic groups and populations (Table 1). Next to contaminated sites, drinking water has been reported to account for up to 75% of total PFAS exposure [73, 74]. Using a compilation of numerous

food samples, dietary survey data and toxicokinetic modeling, EFSA estimated that fish and other seafood dominate the chronic dietary exposure of adults to PFOS (up to 86% of total exposure). For the elderly, EFSA estimated meat and meat products account for up to 52% of PFOS exposure, while eggs and egg products account for up to 42% of infant exposure [57]. For PFOA, EFSA suggested the most important sources of chronic exposure were milk and dairy products for toddlers (up to 86% of exposure), drinking water (up to 60% for infants), and fish and other seafood (up to 56% in elderly).

Human exposures to PFASs (blood PFAS concentrations) are typically estimated using data on measured concentrations in exposure media, contact frequency, and toxicokinetic parameters [23, 25, 74–76]. The reliability of this approach depends on the accuracy of data needed to convert an external dose to internal concentrations. Many of these parameters for PFASs are poorly understood or hard to measure, resulting in large uncertainties about exposure sources (Table 1). For example, Vestergren and Cousins [74] relied on exposure estimates from multiple geographic regions to estimate total PFAS intake from the combination of dietary sources (German data), dust (data from the US and Spain) and inhalation (northwest Europe). Trudel et al. [25] tested a series of scenarios for chemical concentrations and contact frequencies across populations in Europe and

**Table 1** Literature estimates of sources contributions (%) to adult PFAS exposures

PFAS	Diet	Dust	Tap water	Food Pkg.	Inhalation	Dermal	Other	Reference
PFOA	16	11		56	14		2 <sup>a</sup>	Trudel et al. [25]
PFOA	85	6	1	3 <sup>b</sup>			4 <sup>c</sup>	Vestergren and Cousins [74]
PFOA	77	8	11		4			Haug et al. [23]
PFOA	66	9	24		<1	<1		Lorber and Egeghy [76]
PFOA	41		37				22 <sup>d</sup>	Tian et al. [163]
PFOA	99		<1					Shan et al. [164]
PFOS	66	10	7		2		16 <sup>d</sup>	Gebbink et al. [165]
PFOS	72	6	22		<1	<1		Egeghy and Lorber [75]
PFOS	96	1	1		2			Haug et al. [23]
PFOS	81	15					4 <sup>a</sup>	Trudel et al. [25]
PFOS	93		4				3 <sup>d</sup>	Tian et al. [163]
PFOS	100		<1					Shan et al. [164]
PFBA		4	96					Gebbink et al. [165]
PFHxA	38	4	38		8		12 <sup>d</sup>	Gebbink et al. [165]
PFOA	47	8	12		6		27 <sup>d</sup>	Gebbink et al. [165]
PFDA	51	2	4		15		28 <sup>d</sup>	Gebbink et al. [165]
PFDoDA	86	2	2		4		5 <sup>d</sup>	Gebbink et al. [165]

<sup>a</sup>Carpet

<sup>b</sup>Consumer goods

<sup>c</sup>Precursors

<sup>d</sup>Indirect

North America and found plausible ranges in PFAS exposures spanned two orders of magnitude.

Uncertainty in such estimates motivates an alternative solution that uses measured serum concentrations to identify predominant exposure sources. The ratio between two chemical homologues and the correlation among multiple chemical homologues in environmental samples, including human serum, contains information on their origin. This process is referred to as “chemometrics” and has been applied to polychlorinated biphenyls (PCBs), and polycyclic aromatic hydrocarbons (PAHs) [77, 78]. Applying such techniques to PFASs is complicated by dramatic shifts in production over time and the complex metabolism of PFAS precursors. In prior work, researchers have used PFAS isomer profiles to assess the relative contributions from electrochemical fluorination (ECF) and telomere manufacturing to measured PFOA concentrations in the environment [79, 80]. Zhang et al. [81] showed that the measured PFAS composition in surface water provides useful information on sources of environmental pollution. Hu et al. [63] extended this approach to human biomarkers by comparing human serum samples collected at similar time periods and controlling for physiological differences. Using cohort data from the Faroe Islands and the U.S. National Health and Nutrition Examination Survey (NHANES), the authors showed that elevated C9–C12 PFCAs were associated with predominant exposures through seafood consumption. Further, PFHxS and N-EtFOSAA were linked to exposure from consumer products such as carpet and food packaging [63].

Serum samples are routinely collected during epidemiological studies, but environmental samples pertinent to multiple exposure pathways such as drinking water, diet, air, and dust samples are not [82]. Information on contact frequency is often collected using self-reported questionnaires with known recall bias [83]. In addition, there are limited data on chemical half-lives in the human body ( $t_{1/2}$ ) and distribution volumes ( $V_D$ ) for PFASs other than PFOS, PFOA, and PFHxS. This means that traditional exposure modeling is limited to only a few relatively well-characterized individual PFASs and cannot be easily applied to the PFAS mixtures that are more relevant for human exposures.

The results presented in Hu et al. [63] are mostly qualitative and cannot quantify the percentage of PFAS exposure from different exposure pathways. This preliminary approach can be enhanced by expanding the list of PFAS analytes. Regular epidemiological studies usually report six legacy PFASs (branched and linear PFOS, PFOA, PFHxS, PFNA, PFDA) but exposure analyses would be enhanced by including additional PFASs that are increasingly relevant to current production patterns. In addition, a total mass balance is needed to provide quantitative assessments of the

relative importance of different exposure sources [84]. Routine measurements of extractable organic fluorine (EOF) in human sera would thus complement data on individual PFASs and allow such quantitative inferences from the chemometric approach [85, 86].

## Temporal trends in human exposure to PFASs

The presence of organic fluorine in human blood was first detected by Taves [87] in the 1960s. Data on specific forms of organic fluorine such as PFOS and PFOA in human sera were not published until 1990 [88]. Grandjean [89] pointed out that there has been a lag of more than two decades between industry information on exposures and health effects of PFASs and academic research and regulatory action.

Declines in serum concentrations of PFASs following the phase-out in the production of the parent chemical to PFOS and its precursors between 2000 and 2002 have been reported across diverse populations worldwide and provide a success story for the effectiveness of industrial shifts and regulatory actions. These include children from the Faroe Islands [30] and the eastern US [90], adult women from the western US [91] and Sweden [92], the general Australian population [93], and Norwegian men [94]. However, declines in PFOS and PFOA have primarily driven decreasing legacy PFAS concentrations. Concentrations of total PFASs or EOF in human serum that include newer PFASs in production and precursors have not been measured for most populations. One study that examined EOF in human serum in China found the legacy PFASs measured in standard epidemiologic studies only comprised between 30 and 70% of the total fluorine [95]. These results suggest unquantified PFASs may be exhibiting different trends than legacy compounds.

Following the phase-outs in use of PFOS and PFOA in many products, C6-based fluorocarbons (including perfluorohexanesulfonic acid: PFHxS and perfluorohexanoic acid: PFHxA) were used as an initial replacement [96, 97]. Concentrations of PFHxS and PFCAs with 9–14 carbons in human serum have not decreased concomitantly with PFOS, PFOA and their precursors. No change and some increases in exposures to these compounds have been observed across populations. For example, significant increases in PFNA, PFDA, and PFUnDA and no change in PFHxS was observed in Swedish and Danish women through 2015 [92, 98]. Blood concentrations of PFNA, PFDA, PFUnDA, and PFDoDA from multiple countries show no significant change [13]. Similarly, PFHxS concentrations in the blood of Mexican American NHANES participants showed no

significant trend between 1999 and 2004 and increased from 2005 to 2008 [12, 99].

Increasing trends in concentrations of PFHxS and long-chain PFCAs are noteworthy since they significantly contribute to the overall body burden of PFASs and have longer half-lives than both PFOS and PFOA. Additionally, exposures to the C9–C11 PFCAs for some individuals are primarily from seafood consumption [30, 62, 63]. C9–C11 PFCAs exhibit different temporal patterns than PFOS and PFOA. They are bioaccumulative and concentrations in some seafood have been increasing, as discussed in Dasuncao et al. [30]. This suggests that while exposures to PFOS and PFOA have been successfully reduced by product phase-outs for many populations, exposures to C9–C11 PFCAs have not followed the same trends.

## Health effects associated with exposure to PFASs

The 3M Company was the major global manufacturer of PFASs in the 1990s and conducted most of the early studies on the health effects of PFAS exposures in animals and humans [26, 100]. Many of these studies were not published in the peer-reviewed literature but can be found in the U.S. EPA public docket AR-226, and are reviewed in the section below.

### Early industry studies

Before 1980, 3M conducted multiple studies of acute animal toxicity associated with exposure to legacy PFASs [101]. Serum PFAS concentrations measured as organic fluorine in 3M workers were ten times higher than the general population in 1980 [102]. Shortly after this, 3M carried out a series of subacute and chronic studies in various animal models such as rats, mice, and monkeys [103–105]. Results showed N-ethyl perfluorooctane sulfonamidoethanol (N-EtFOSE) was carcinogenic in rats after a 2-year chronic study concluded in 1988. However, the results were first misinterpreted as a null finding and only corrected a decade later [106, 107]. In a 90-day rhesus monkey study, all monkeys in all treatment groups died after 20 days and the study had to be aborted [104]. In later monkey studies with lower doses, reductions in total cholesterol, increased liver weight, and toxicity on the reticuloendothelial system (immune system) were observed [103].

Health surveillance of 3M workers produced inconsistent results, mainly due to small sample sizes and a scenario known in epidemiology literature as the “healthy worker effect” [108]. A doctoral thesis that focused on a cohort of 3M workers reported in 1992 that PFOA exposure may significantly alter male reproductive hormones and

leukocyte counts [109]. Later investigations published by 3M did not find the same associations [110]. Differences between these findings may be caused by the exposure assessment methods used: Gilliland [109] measured serum total organic fluorine while Olsen [110] measured serum PFOA concentrations. This suggests adverse effects observed in Gilliland’s work [109] may have result from exposures to fluorochemicals other than PFOA.

### Academic studies

Most academic research on PFASs was initiated in the early 2000s after the voluntary phase-out in the production of the parent chemical to PFOS and its precursors by 3M, the major global manufacturer at the time. Results from experimental studies in rodents can be challenging to translate directly to human health impacts because of differences in peroxisome proliferation expression, which is one of the main mechanisms of PFASs toxicity [111]. The most comprehensive longitudinal evidence for adverse health effects associated with PFAS exposure (C8 Health Project) is from the population living near the West Virginia DuPont Washington Works fluorotelomer plant. Probable links between PFOA exposure and six diseases have been identified: high cholesterol, thyroid disease, pregnancy-induced hypertension, ulcerative colitis, and kidney and testicular cancer [112–115].

Children may be more vulnerable to PFAS exposures because they often have higher body burdens than adults and are going through sensitive windows for development. A recent systematic review of the children’s health literature identified positive associations between PFAS exposures and dyslipidemia, immunity, renal function, and age at menarche [116]. Some health effects such as immunotoxicity can be detected at lower exposure levels than others. For example, Grandjean et al. [117] examined the impact of serum PFAS concentrations on serum antibody production in children at ages 5 and 7 years following routine vaccinations for tetanus and diphtheria. A doubling of serum PFOS, PFOA, and PFHxS concentrations at age 5 was associated with a 50% decline in antibody concentrations at age 7. If this effect is causal, average serum concentrations in the general population of most countries with biomonitoring data greatly exceed the benchmark doses of 1.3 ng/mL for PFOS and 0.3 ng/mL for PFOA calculated based on immunotoxicity in children [48].

### Cancer

Numerous studies have investigated PFAS carcinogenicity, mainly focusing on PFOA and PFOS. PFHxA is the only other PFAS that has been investigated in an animal study and null findings were reported [118]. Human studies for



PFOS and PFOA include chemical workers, communities with contaminated drinking water, and the general population. A 3.3-fold increase (95% CI, 1.02–10.6) in prostate cancer mortality was reported for each month spent in the chemical division with PFOA production was observed among occupationally exposed workers, but the number of cases was small [119]. Later data from this occupational cohort did not support an association between occupational exposure and cancer mortality or incidence [120]. The strongest evidence for increased cancer risk has been reported by studies among community members whose drinking water was contaminated by PFOA. Barry et al. [112] and Vieira et al. [121] showed a positive association between PFOA levels and kidney and testicular cancers among participants in the C8 Health Project. These studies form the foundation of the overall conclusion from the C8 Health Project. Results among studies conducted in general population are inconsistent. Eriksen et al. [122] were the first to examine PFOA exposure and cancer in the general population and they did not find an association between plasma PFOA or PFOS concentration and prostate, bladder, pancreatic, or liver cancer. The International Agency for Research on Cancer (IARC) classified PFOA as a possibly carcinogenic to humans (Group 2B). No IARC evaluation is available for PFOS.

## Immune effects

Immunotoxicity of PFASs has been demonstrated in multiple animal models, including rodents, birds, reptiles and other mammalian and non-mammalian wildlife. Epidemiological data is relatively sparse but mounting evidence suggests that the immunotoxic effects in laboratory animal

models occur at serum concentrations that are comparable to body burden of highly exposed humans and wildlife [123].

Table 2 shows findings from a review of 25 epidemiological studies published between 2008 and 2018. Cohort data were from China, Denmark, the Faroe Islands, Japan, Norway, Taiwan, and the US and 14 out of the 25 studies reviewed were longitudinal. Two studies focused on occupational exposures and the remaining 23 were based on environmental exposures. Infants and children were the most studied demographic group for this health endpoint and accounted for 16 out of the 25 studies. Three studies considered data from teenagers in the U.S. NHANES survey. Six studies were based on either residents or workers from the C8 health project near a fluorotelomer plant in West Virginia. One study examined a group of healthy adults who received vaccination. Serum PFAS concentration measurements were the most widely used exposure assessment method, accounting for 22 out of 25 studies. Four studies from the C8 health project used job-exposure matrix or residential history to estimate lifetime cumulative exposures.

The health outcomes related to PFAS immunotoxicity include both molecular-level (i.e., antibody concentrations) and organ/system-level (i.e., infection of the respiratory system). In general, more consistent results across different studies were reported for molecular-level health endpoints such as vaccine antibody or other immune markers such as immunoglobulin (Table 1).

Five studies examined the association between PFAS exposure and suppression of antibody response to vaccination among children, adolescents or adults. Four out of the five found statistically significant associations between

**Table 2** Summary of the epidemiologic literature on PFAS exposures and metabolic outcomes

Outcome	# of total studies	# of studies by results				Other PFASs
		PFOA	PFNA	PFHxS	PFOS	
Lipid profile <sup>a</sup>	39	21/10/1 <sup>b</sup>	8/1/2	4/4/2	20/9/3	Inconsistent results for PFDA, PFUnDA, PFTeDA
Insulin resistance and diabetes	18	6/9/1	3/5/0	1/2/1	7/4/1	Mostly null for PFDA, PFUnDA, PFDoDA, N-EtFOSAA, N-MeFOSAA; One positive finding for PFDoDA and insulin resistance
Hypertension, vascular disease and stroke	10	3/5/1	3/0/1	0/3/1	1/3/1	Only one study reported null for PFDA and PFUnDA
Thyroid disease	8	4/3/0	1/2/0	1/2/0	1/3/0	Positive finding for PFDA and PFUnDA in two studies. Null for PFTeDA
Cardiovascular disease	6	1/4/1	1/0/0	0/1/0	0/1/0	No other PFASs have been investigated
Uric acid	5	4/0/0	0/0/0	0/1/0	2/2/0	No other PFASs have been investigated
Overweight and obese	4	1/3/0	1/1/0	1/1/0	3/1/0	Positive finding for PFDA in only one study (Liu et al. [134])

Details of the studies examined are provided in the Supporting Information Table S1

<sup>a</sup>Lipid profile includes low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglycerides

<sup>b</sup>Number of studies with adverse/null/protective results

higher PFAS exposure and suppressed immune response. Grandjean et al. [117] were the first to link PFAS exposure in children to deficits in immune function. The authors reported a 2-fold increase of major PFASs in child serum was associated with a  $-49%$  (95% confidence interval (CI),  $-67%$  to  $-23%$ ) decline in tetanus and diphtheria antibody concentrations. This effect size is larger than later studies and can be attributed to different exposure levels, different vaccine strains, and different times elapsed since vaccination (peak antibodies vs. residual antibodies). Other studies have not examined tetanus and diphtheria, but similar associations have been found in PFAS exposure and other childhood vaccinations such as rubella and mumps [124, 125], and adult influenza vaccination such as FluMist [126] and anti-H3N2 [127].

Five out of seven studies that examined associations between PFAS exposure and immune markers found statistically significant evidence of immunosuppression. The strongest evidence has been generated for PFOA and PFOS with limited data for other PFASs. One example for other PFASs is from a case-control study in Taiwan [128] that reported that among children with asthma, nine out of the ten PFASs evaluated were positively associated with at least two of the three immunological biomarkers (immunoglobulin E (IgE), absolute eosinophil counts (AEC), and eosinophilic cationic protein (ECP)). However, this study did not account for the fact that multiple PFASs serum concentrations are positively correlated and therefore did not distinguish whether all PFASs or a subset of PFASs were associated with immune suppression.

Results with organ/system-level outcomes such as asthma, infection, and allergies are more inconsistent. Slightly more than half of the studies on asthma and infection show statistically significant results. Similar to the molecular-level outcomes, stronger evidence has been established for PFOS and PFOA than other more minor PFASs. Buser et al. [129] found serum levels of PFASs were associated with higher odds of self-reported food allergies among teenagers in NHANES 2007–2010. This is the only study out of the six studies reviewed with a statistically significant finding, but the cross-sectional design of this study necessitates further investigation using longitudinal studies. Existing studies have limitations such as outcome measurement error. For example, some studies measure asthma using a self-reported questionnaire but did not validate these data with medical records. Some studies used hospitalization due to infection as an outcome but hospitalization may not be necessary for most infections. In addition, since infection and allergy be caused by food and airborne allergens, it is challenging to identify the contribution of PFAS exposures in a low signal-to-noise setting.

## Metabolic effects

We reviewed 69 epidemiological studies published between 1996 and 2018 based on human populations in Australia, Canada, China, several European countries, Japan, South Korea, Taiwan, UK, and the US. We identified 26 out of 69 studies as longitudinal and 59 out of 69 studies were based on environmental exposures. Diverse demographic groups have been studied for this health endpoint, including infants, mother–child pairs, children, teenagers, adults, workers, and special subpopulations such as diabetic patients and obese individuals in randomized clinical trials. Measured serum PFAS concentrations were the most widely used exposure assessment method (65 out of 69 studies). Two occupational studies used job-exposure matrix and work history to estimate lifetime cumulative exposures. Gilliland [130] was the earliest study and used total serum fluorine to quantify the exposure. Only one study [131] examined the different isomers of PFOA and PFOS (linear vs. branched) using data from NHANES 2013–2014.

There is relatively consistent evidence of modest positive associations with lipid profiles such as total cholesterol and triglycerides, although the magnitude of the cholesterol effect is inconsistent across different exposure levels. There is some but much less consistent evidence of a modest positive correlation with metabolic diseases such as diabetes, overweight, obesity, and heart diseases (Table 3). The majority of studies are cross-sectional, which have limited causal interpretation [132]. A few studies provided stronger evidence than observational studies, such as Diabetes Prevention Program Trial [133] and a diet-induced weight-loss trial [134].

The majority of the studies examined found associations between elevated serum PFASs and detrimental lipid profiles, such as elevated total cholesterol and low-density lipoprotein cholesterol (LDL-C), or reduced high-density lipoprotein cholesterol (HDL-C). PFOS and PFOA exhibit the most consistent finding across studies. The effect size varies across studies, which can be a result of different exposure levels. Increases in serum PFOA and PFOS from the lowest to the highest quintiles among children in C8 health project was associated with 4.6 and 8.5 mg/dL total cholesterol (reference level for children is  $<170$  mg/dL) [135]. Among NHANES 2003–2004 participants, increases in serum PFOA and PFOS from the lowest to the highest quartiles were associated with 9.8 and 13.4 mg/dL total cholesterol (reference level for adults is  $<200$  mg/dL) [136]. Maisonet et al. [137] reported a non-linear relationship between prenatal PFOA concentrations and total cholesterol at ages 7 and 15 of the child.

Eighteen studies have examined the associations between PFAS exposures and glucose metabolism, insulin resistance, and diabetes. Overall the results across different

**Table 3** Summary of the epidemiologic literature on PFAS exposures and immunotoxicity

Outcome	# of total studies	# of significant studies	# of significant studies by each PFAS
Vaccine antibody	5	4	Mixture: 1; PFOA: 2; PFNA: 1; PFHxS: 1; PFOS: 2
Immune markers	7	5	PFHpA: 1; PFOA: 5; PFNA: 2; PFDA: 1; PFTeDA: 1; PFDoA: 1; PFBS: 1; PFHxS: 2; PFOS: 4
Asthma and biomarker of asthma	9	5	PFHpA: 1; PFOA: 5; PFNA: 3; PFDA: 3; PFDoDA: 1; PFBS: 1; PFHxS: 2; PFOS: 4
Infection and other autoimmune diseases	13	8	PFOA: 6; PFOS: 4; PFDA: 1; PFDoDA: 1; PFNA: 2; PFUnDA: 1; PFHxS: 1; PFOSA: 1
Allergy	6	1	PFOA: 1; PFHxS: 1; PFOS: 1

Details of the studies examined are provided in the Supporting Information Table S2

studies are inconclusive. Lin et al. [138] were the first to report a positive association between serum PFAS concentrations and glucose homeostasis among adults and adolescents in NHANES. They reported a considerable effective size—doubling serum PFNA concentrations was associated with hyperglycemia odds ratio (OR) of 3.16 (95% CI 1.39–7.16). Later studies tend to report smaller effect sizes. Exposure during pregnancy may affect the mother and child during gestation and later in life. In a small pregnancy cohort in the US, each standard deviation of increase in PFOA was associated with a 1.87-fold increase of gestational diabetes risk (95% CI 1.14–3.02) [139]. In a larger Spanish cohort, a null result was reported for PFOA, but PFOS, PFHxS, and gestational diabetes had positive associations: OR per log10-unit increase = 1.99 (95% CI: 1.06, 3.78) and OR = 1.65 (95% CI: 0.99, 2.76), respectively [140].

Results for hypertension and other vascular diseases including stroke are also inconsistent. Two of the earliest studies examined the relationship between PFAS exposure and hypertension among NHANES and found different results for children and adults. Adjusted OR = 2.62 for hypertension comparing 80th vs. 20th percentiles serum PFOA among NHANES adults in the US [141], while among children a null finding was reported [142]. In some later cohort studies, null results and even protective effects associated with PFAS exposure and hypertension were reported [143, 144]. A cross-sectional study on carotid artery intima-media thickness in adolescents reported increased risks with an increase in plasma PFOS [145]. However, a more recent study on artery stiffness found protective effects of PFOA and PFNA among children and adolescents enrolled in the World Trade Center Health Registry [146].

Other metabolic endpoints include thyroid disease (which could also be considered an endpoint for endocrine disruption), cardiovascular diseases, uric acid metabolism, and body weight. Except for uric acid metabolism, most results are inconclusive. An increase in hyperuricemia risks and PFOA exposure was observed in all four studies (two from NHANES and two from C8 Health Project).

In summary, the strongest evidence for a relationship between PFAS exposure and metabolic outcome is in the area of dyslipidemia. Animal studies have found decreases in serum cholesterol levels associated with increased PFAS exposures, which contradicts epidemiological findings. The difference may lie in different levels of expression for nuclear receptors involved in the toxicological pathway, such as peroxisome proliferator-activated receptor (PPAR)-alpha. It may also be related to differences in exposure levels. Dietary factors can influence metabolic outcomes [147], introducing bias into observed relationships if not controlled for properly. Explanations for null findings

include healthy worker effects and non-linear relationships, such as decreasing slopes as exposure increases (log-linear relationships) [148].

### Neurodevelopmental effects

In vitro studies suggest PFOS can trigger the “opening” of tight junction in brain endothelial cells and increase the permeability of the blood brain barrier [149]. There has therefore been some interest in investigating the neurotoxic effects associated with PFAS exposures. In laboratory animals, it has been reported that PFOS, PFOA, and PFHxS exposures during the peak time of rapid brain growth in mice resulted in an inability to habituate in the unfamiliar environment [150]. Liew et al. [151] reviewed 21 epidemiological studies in 2018 and concluded that evidence is mixed regarding neurodevelopmental effects of PFAS exposures. Health outcomes examined included developmental milestones in infancy, attention-deficit/hyperactivity disorder (ADHD) and behaviors in childhood, and neuropsychological functions such as IQ and other scales or scores. Neurodevelopmental trajectories are highly complicated and there is great heterogeneity in the instruments and methods to evaluate neurodevelopmental endpoints. Additional research is needed to establish a link between neurodevelopmental outcomes and PFAS exposures.

### Future directions

Challenges associated with quantifying the full-diversity of individual PFASs present in environmental samples and a paucity of toxicity data highlight the need for data and tools to better understand new and emerging fluorinated compounds. EOF provides an estimate of all combustible organofluorine compounds present and provides a proxy measure for unquantified PFASs [86]. Yeung and Mabury [152] reported that quantifiable PFASs accounted for 52–100% of EOF in human plasma samples collected between 1982 and 2009 in two German cities. The amount and proportion of unidentified organofluorine in human plasma increased after 2000 in one city. This study hypothesized that humans are exposed to many new and unidentified organofluorine compounds, which is consistent with the environmental exposure literature [3, 74, 153, 154].

The toxicity of new and emerging PFASs for ecosystems and humans is poorly understood. This is problematic because in communities with high concentrations of alternative PFASs, the magnitude of potential health impacts associated with exposures has not been quantified and such information is generally considered necessary to engage in risk mitigation actions. Chemical manufacturers have claimed that replacement PFASs are not associated with

adverse health effects and that shorter-chain homologues with shorter half-lives in the human body are not likely to bioaccumulate [155, 156]. However, ongoing work suggests shorter chain compounds have a higher potential to interact with biomolecules due to less steric hindrance than the longer chain homologues [157, 158]. For example, fluorinated carbon chains in perfluoroalkyl ether carboxylic acids (PFECAs), an important new class of PFASs, are broken into shorter units by the insertion of oxygen molecules that are thought to make them more reactive [159]. One known PFOA alternative is the ammonium salt of perfluoro-2-propoxypropanoic acid, a PFECA that has been produced since 2010 with the trade name “GenX” [160]. A recent hazard assessment based on the internal dose of GenX suggests it has higher toxicity than PFOA after accounting for toxicokinetic differences [18]. The extreme environmental persistence, bioaccumulation, and potential toxicity of the entire class of PFASs has led some researchers to question the use of any highly fluorinated chemicals and call for a class approach in managing them [161].

In summary, additional research is needed to better understand the exposure pathways and health outcomes associated with emerging PFASs and to understand the timescales of exposures to legacy PFASs associated with drinking water and seafood contamination. Risk mitigation measures require new technology for reducing PFAS concentrations at contaminated sites and in drinking water supplies. Delayed action on legacy PFASs has resulted in widespread human exposures and risks and lessons should be learned from this example and not repeated for the newer PFASs entering the market [89]. Although additional data are needed to understand the full extent of impacts of PFAS exposures on human health, particularly at sensitive life stages, we assert that this should not be used as a justification for delaying risk mitigation actions. The phase-out in PFOS and its precursors between 2000 and 2002 was extremely effective at rapidly reducing exposures of humans and wildlife globally to these compounds and provides an example of the potential benefits from the coordinated global action.

**Acknowledgements** Financial support for this work was provided by the NIH Superfund Research Program P42ES027706 and the Harvard National Institute of Environmental Health and Sciences (NIEHS) Center Grant (P30 ES000002).

### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

## References

- OECD (The Organisation for Economic Co-operation and Development). Toward a new comprehensive global database of per- and polyfluoroalkyl substances (PFASs): summary report on updating the OECD 2007 list of per and polyfluoroalkyl substances (PFASs); 2018.
- Vecitis CD, Wang Y, Cheng J, Park H, Mader BT, Hoffmann MR. Sonochemical degradation of perfluorooctane sulfonate in aqueous film-forming foams. *Environ Sci Technol*. 2010;44:432–8.
- Wang Z, DeWitt JC, Higgins CP, Cousins ITA. Never-ending story of per- and polyfluoroalkyl substances (PFASs)? *Environ Sci Technol*. 2017;51:2508–18.
- Hu XC, Andrews DQ, Lindstrom AB, Bruton TA, Schaidler LA, Grandjean P, et al. Detection of poly- and perfluoroalkyl substances (PFASs) in U.S. drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. *Environ Sci Technol Lett*. 2016;3:344–50.
- Banzhaf S, Filipovic M, Lewis J, Sparrenbom C, Barthel R. A review of contamination of surface-, ground, and drinking water in Sweden by perfluoroalkyl and polyfluoroalkyl substances (PFASs). *Ambio*. 2017;46:335–46.
- Wang Z, Cousins IT, Scheringer M, Hungerbuehler K. Hazard assessment of fluorinated alternatives to long-chain perfluoroalkyl acids (PFAAs) and their precursors: status quo, ongoing challenges and possible solutions. *Environ Int*. 2015;75:172–9.
- Armitage J, Cousins IT, Buck RC, Prevedouros K, Russell MH, MacLeod M, et al. Modeling global-scale fate and transport of perfluorooctanoate emitted from direct sources. *Environ Sci Technol*. 2006;40:6969–75.
- Giesy J, Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. *Environ Sci Technol*. 2001;35:1339–42.
- Tomy G, Budakowski W, Halldorson T, Helm P, Stern G, Friesent K, et al. Fluorinated organic compounds in an eastern Arctic marine food web. *Environ Sci Technol*. 2004;38:6475–81.
- Lewis RC, Johns LE, Meeker JD. Serum biomarkers of exposure to perfluoroalkyl substances in relation to serum testosterone and measures of thyroid function among adults and adolescents from NHANES 2011–2012. *Int J Environ Res Public Health*. 2015;12:6098–114.
- CDC. Fourth national report on human exposure to environmental chemicals. Atlanta: Centers for Disease Control and Prevention; 2015.
- Calafat AM, Wong L-Y, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and comparisons with NHANES 1999–2000. *Environ Health Perspect*. 2007;115:1696–702.
- Land M, de Wit CA, Cousins IT, Herzke D, Johansson J, Martin JW. What is the effect of phasing out long-chain per- and polyfluoroalkyl substances on the concentrations of perfluoroalkyl acids and their precursors in the environment? A systematic review protocol. *Environ Evid*. 2015;4:3
- Gomis MI, Vestergren R, MacLeod M, Mueller JF, Cousins IT. Historical human exposure to perfluoroalkyl acids in the United States and Australia reconstructed from biomonitoring data using population-based pharmacokinetic modelling. *Environ Int*. 2017;108:92–102.
- Okada E, Kashino I, Matsuura H, Sasaki S, Miyashita C, Yamamoto J, et al. Temporal trends of perfluoroalkyl acids in plasma samples of pregnant women in Hokkaido, Japan, 2003–2011. *Environ Int*. 2013;60:89–96.
- Nøst TH, Vestergren R, Berg V, Nieboer E, Odland JØ, Sandanger TM. Repeated measurements of per- and polyfluoroalkyl substances (PFASs) from 1979 to 2007 in males from Northern Norway: assessing time trends, compound correlations and relations to age/birth cohort. *Environ Int*. 2014;67:43–53.
- Ritscher A, Wang Z, Scheringer M, Boucher JM, Ahrens L, Berger U et al. Zürich Statement on future actions on per- and polyfluoroalkyl substances (PFASs). *Environ Health Perspect*. 2018. <https://doi.org/10.1289/EHP4158>.
- Gomis MI, Vestergren R, Borg D, Cousins IT. Comparing the toxic potency in vivo of long-chain perfluoroalkyl acids and fluorinated alternatives. *Environ Int*. 2018;113:1–9.
- Buck RC, Franklin J, Berger U, Conder JM, Cousins IT, de Voogt P, et al. Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins. *Integr Environ Assess Manag*. 2011;7:513–41.
- Butt CM, Muir DCG, Mabury SA. Biotransformation pathways of fluorotelomer-based polyfluoroalkyl substances: a review. *Environ Toxicol Chem*. 2014;33:243–67.
- Young C, Mabury S. Atmospheric perfluorinated acid precursors: chemistry, occurrence, and impacts. *Rev Environ Contam Toxicol*. 2010;208:1–109.
- Pickard H, Criscitiello A, Spencer C, Sharp M, Muir D, De Silva A, et al. Continuous non-marine inputs of per- and polyfluoroalkyl substances to the High Arctic: a multi-decadal temporal record. *Atmos Chem Phys*. 2018;18:5045–58.
- Haug LS, Huber S, Becher G, Thomsen C. Characterisation of human exposure pathways to perfluorinated compounds—comparing exposure estimates with biomarkers of exposure. *Environ Int*. 2011;37:687–93.
- Vestergren R, Cousins IT, Trudel D, Wormuth M, Scheringer M. Estimating the contribution of precursor compounds in consumer exposure to PFOS and PFOA. *Chemosphere*. 2008;73:1617–24.
- Trudel D, Horowitz L, Wormuth M, Scheringer M, Cousins IT, Hungerbuehler K. Estimating consumer exposure to PFOS and PFOA. *Risk Anal*. 2008;28:251–69.
- 3M Company. Fluorochemical use, distribution and release overview. US EPA Public Docket AR226-0550. St Paul, MN: 3M Company; 1999.
- Kissa, E. Fluorinated Surfactants and Repellents, 2nd ed.; Vol. 97 in Surfactant Science Series; Marcel Dekker: New York, 2001.
- Dassuncao C, Hu XC, Zhang X, Bossi R, Dam M, Mikkelsen B, et al. Temporal shifts in poly- and perfluoroalkyl substances (PFASs) in North Atlantic pilot whales indicate large contribution of atmospheric precursors. *Environ Sci Technol*. 2017;51:4512–21.
- Zhang X, Zhang Y, Dassuncao C, Lohmann R, Sunderland EM. North Atlantic deep water formation inhibits high Arctic contamination by continental perfluorooctane sulfonate discharges. *Glob Biogeochem Cycles*. 2017;31:1332–43.
- Dassuncao C, Hu XC, Nielsen F, Weihe P, Grandjean P, Sunderland EM. Shifting global exposures to poly- and perfluoroalkyl substances (PFASs) evident in longitudinal birth cohorts from a seafood-consuming population. *Environ Sci Technol*. 2018. <https://doi.org/10.1021/acs.est.7b06044>.
- Favreau P, Poncioni-Rothlisberger C, Place BJ, Bouchex-Bellomie H, Weber A, Tremp J, et al. Multianalyte profiling of per- and polyfluoroalkyl substances (PFASs) in liquid commercial products. *Chemosphere*. 2017;171:491–501.
- Robel AE, Marshall K, Dickinson M, Lunderberg D, Butt C, Peaslee G, et al. Closing the mass balance on fluorine on papers and textiles. *Environ Sci Technol*. 2017;51:9022–32.
- Herzke D, Olsson E, Posner S. Perfluoroalkyl and polyfluoroalkyl substances (PFASs) in consumer products in Norway—a pilot study. *Chemosphere*. 2012;88:980–7.

34. Schaidler LA, Balan SA, Blum A, Andrews DQ, Strynar MJ, Dickinson ME, et al. Fluorinated compounds in U.S. fast food packaging. *Environ Sci Technol Lett.* 2017;4:105–11.
35. Guo Z, Liu X, Krebs AK. Perfluorocarboxylic acid content in 116 articles of commerce: EPA?600/R-09/-33. Research Triangle Park, NC: Environmental Protection Agency; 2009.
36. Yuan G, Peng H, Huang C, Hu J. Ubiquitous occurrence of fluorotelomer alcohols in eco-friendly paper-made food-contact materials and their implication for human exposure. *Environ Sci Technol.* 2016;50:942–50.
37. Zabaleta I, Bizkarguenaga E, Bilbao D, Etxebarria N, Prieto A, Zuloaga O. Fast and simple determination of perfluorinated compounds and their potential precursors in different packaging materials. *Talanta.* 2016;152:353–63.
38. Kotthoff M, Müller J, Jüriling H, Schlummer M, Fiedler D. Perfluoroalkyl and polyfluoroalkyl substances in consumer products. *Environ Sci Pollut Res.* 2015;22:14546–59.
39. Ye F, Zushi Y, Masunaga S. Survey of perfluoroalkyl acids (PFAAs) and their precursors present in Japanese consumer products. *Chemosphere.* 2015;127:262–8.
40. Bečanová J, Melymuk L, Vojta Š, Komprdová K, Klánová J. Screening for perfluoroalkyl acids in consumer products, building materials and wastes. *Chemosphere.* 2016;164:322–9.
41. Begley TH, White K, Honigfort P, Twaroski ML, Neches R, Walker RA. Perfluorochemicals: potential sources of and migration from food packaging. *Food Addit Contam.* 2005;22:1023–31.
42. Begley TH, Hsu W, Noonan G, Diachenko G. Migration of fluorochemical paper additives from food-contact paper into foods and food simulants. *Food Addit Contam: Part A.* 2008;25:384–90.
43. Harrad S, de Wit C, Abdallah M, Bergh C, Bjorklund J, Covaci A, et al. Indoor contamination with hexabromocyclododecanes, polybrominated diphenyl ethers, and perfluoroalkyl compounds: an important exposure pathway for people? *Environ Sci Technol.* 2010;44:3221–31.
44. Fromme H, Dreyer A, Dietrich S, Fembacher L, Lahrz T, Völkel W. Neutral polyfluorinated compounds in indoor air in Germany—the LUPE 4 study. *Chemosphere.* 2015;139:572–8.
45. US EPA. Lifetime health advisories and health effects support documents for perfluorooctanoic acid and perfluorooctane sulfonate. Washington, DC: Environmental Protection Agency; 2016. [https://www.epa.gov/sites/production/files/2016-05/documents/pfoa\\_pfos\\_prepub\\_508.pdf](https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_pfos_prepub_508.pdf) [Accessed 31 August 2018].
46. ATSDR. Toxicological profile for perfluoroalkyls: draft for public comment, June 2018. Atlanta, GA: Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services; 2018. Available: <https://www.atsdr.cdc.gov/toxprofiles/tp200.pdf> [Accessed 31 August 2018].
47. Health Canada. Health Canada's drinking water screening values for perfluoroalkylated substances (PFASs). Ottawa, ON; February 2016. Available: <http://scotttreid.ca/wp-content/uploads/2016/03/Health-Canada-PFAS-Screening-Values-Fact-Sheet-EN.pdf> [Accessed 20 August 2018].
48. Grandjean P, Budtz-Jørgensen E. Immunotoxicity of perfluorinated alkylates: calculation of benchmark doses based on serum concentrations in children. *Environ Health.* 2013;12:35.
49. Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. *J Occup Environ Med/Am Coll Occup Environ Med.* 2006;48:759–70.
50. Post GB, Louis JB, Cooper KR, Boros-Russo BJ, Lippincott RL. Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems. *Environ Sci Technol.* 2009;43:4547–54.
51. US EPA. The Third Unregulated Contaminant Monitoring Rule (UCMR 3): Data Summary, April 2016. Office of Water, EPA 815-S-16-002; 2016.
52. Sun M, Arevalo E, Strynar M, Linstrom A, Richardson M, Kearns B, et al. Legacy and emerging perfluoroalkyl substances are important drinking water contaminants in the Cape Fear River watershed of North Carolina. *Environ Sci Technol Lett.* 2016;3:415–9.
53. Lindh CH, Rylander L, Toft G, Axmon A, Rignell-Hydbom A, Giwercman A, et al. Blood serum concentrations of perfluorinated compounds in men from Greenlandic Inuit and European populations. *Chemosphere.* 2012;88:1269–75.
54. Weihe P, Kato K, Calafat AM, Nielsen F, Wanigatunga A, Needham L, et al. Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. *Environ Sci Technol.* 2008;42:6291–5.
55. Zhou Z, Shi Y, Vestergren R, Wang T, Liang Y, Cai Y. Highly elevated serum concentrations of perfluoroalkyl substances in fishery employees from Tangxun Lake, China. *Environ Sci Technol.* 2014;48:3864–74.
56. Berger U, Glynn A, Holmstrom K, Berglund M, Ankarberg E, Tomkvist A. Fish consumption as a source of human exposure to perfluorinated alkyl substances in Sweden—analysis of edible fish from Lake Vattern and the Baltic Sea. *Chemosphere.* 2009;76:799–804.
57. European Food Safety Authority. Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food (draft). *EFSA J.* 2018;16:1–293.
58. Stahl L, Snyder B, Olsen A, Kinkaid T, Wathen J, McCarty H. Perfluorinated compounds in fish from U.S. urban rivers and the Great Lakes. *Sci Total Environ.* 2014;499:185–95.
59. Del Gobbo L, Tittlemier S, Diamond M, Pepper K, Tague B, Yeudall F, et al. Cooking decreases observed perfluorinated compound concentrations in fish. *J Agric Food Chem.* 2008;56:7551–9.
60. Kelly B, Ikonou M, Blair J, Surridge B, Hoover D, Grace R, et al. Perfluoroalkyl contaminants in an Arctic marine food web: trophic magnification and wildlife exposure. *Environ Sci Technol.* 2009;43:4037–43.
61. Condor J, Hoke R, de Wolf W, Russell MH, Buck RC. Are PFCAs bioaccumulative? A critical review and comparison with regulatory criteria and persistent lipophilic compounds. *Environ Sci Technol.* 2008;42:995–1003.
62. Christensen K, Raymond M, Blackowicz M, Liu Y-J, Thompson B, Anderson H, et al. Perfluoroalkyl substances and fish consumption. *Environ Res.* 2017;154:145–51.
63. Hu XC, Dassuncao C, Zhang X, Grandjean P, Weihe P, Webster G, et al. Can profiles of poly- and perfluoroalkyl substances (PFASs) in human serum provide information on major exposure sources. *Environ Health.* 2018;17. <https://doi.org/10.1186/s12940-12018-10355-12944>.
64. Buser A, Morf L. Substance flow analysis of PFOS and PFOA. In: Perfluorinated surfactants perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA) in Switzerland. Bern, Switzerland: Federal Office for the Environment (FOEN); 2009.
65. Earnshaw MR, Paul AG, Loos R, Tavazzi S, Paracchini B, Scheringer M, et al. Comparing measured and modelled PFOS concentrations in a UK freshwater catchment and estimating emission rates. *Environ Int.* 2014;70:25–31.
66. Sepulvado JG, Blaine AC, Hundal LS, Higgins CP. Occurrence and fate of perfluorochemicals in soil following the land application of municipal biosolids. *Environ Sci Technol.* 2011;45:8106–12.
67. Washington JW, Yoo H, Ellington JJ, Jenkins TM, Libelo EL. Concentrations, distribution, and persistence of

- perfluoroalkylates in sludge-applied soils near Decatur, Alabama, USA. *Environ Sci Technol.* 2010;44:8390–6.
68. Venkatesan AK, Halden RU. National inventory of perfluoroalkyl substances in archived U.S. biosolids from the 2001 EPA National Sewage Sludge Survey. *J Hazard Mater.* 2013;252–253:413–8.
  69. Navarro I, de la Torre A, Sanz P, Pro J, Carbonell G, de los Ángeles Martínez M. Bioaccumulation of emerging organic compounds (perfluoroalkyl substances and halogenated flame retardants) by earthworm in biosolid amended soils. *Environ Res.* 2016;149:32–9.
  70. Navarro I, de la Torre A, Sanz P, Porcel MÁ, Pro J, Carbonell G, et al. Uptake of perfluoroalkyl substances and halogenated flame retardants by crop plants grown in biosolids-amended soils. *Environ Res.* 2017;152:199–206.
  71. Wen B, Wu Y, Zhang H, Liu Y, Hu X, Huang H, et al. The roles of protein and lipid in the accumulation and distribution of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in plants grown in biosolids-amended soils. *Environ Pollut.* 2016;216:682–8.
  72. Domingo JL, Nadal M. Per- and polyfluoroalkyl substances (PFASs) in Food and human dietary intake: a review of the recent scientific literature. *J Agric Food Chem.* 2017;56:533–43.
  73. Hoffman K, Webster T, Bartell S, Weisskopf M, Fletcher T, Vieira V. Private drinking water wells as a source of exposure to perfluorooctanoic acid (PFOA) in communities surrounding a fluoropolymer production facility. *Environ Health Perspect.* 2010;119:92–7.
  74. Vestergren R, Cousins IT. Tracking the pathways of human exposure to perfluorocarboxylates. *Environ Sci Technol.* 2009;43:5565–75.
  75. Egeghy PP, Lorber M. An assessment of the exposure of Americans to perfluorooctane sulfonate: a comparison of estimated intake with values inferred from NHANES data. *J Expo Sci Environ Epidemiol.* 2011;21:150–68.
  76. Lorber M, Egeghy PP. Simple intake and pharmacokinetic modeling to characterize exposure of Americans to perfluorooctanoic acid, PFOA. *Environ Sci Technol.* 2011;45:8006–14.
  77. Johnson GW, Ehrlich R, Full W, Ramos S. Principal components analysis and receptor models in environmental forensics. San Diego: Academic Press; 2002.
  78. Wang Z, Stout SA, Fingas M. Forensic fingerprinting of biomarkers for oil spill characterization and source identification. *Environ Forensics.* 2006;7:105–46.
  79. Benskin JP, Phillips V, St Louis VL, Martin JW. Source elucidation of perfluorinated carboxylic acids in remote alpine lake sediment cores. *Environ Sci Technol.* 2011;45:7188–94.
  80. D'eon JC, Mabury SA. Exploring indirect sources of human exposure to perfluoroalkyl carboxylates (PFCAs): evaluating uptake, elimination, and biotransformation of polyfluoroalkyl phosphate esters (PAPs) in the rat. *Environ Health Perspect.* 2011;119:344.
  81. Zhang X, Lohmann R, Dassuncao C, Hu XC, Weber AK, Vecitis CD, et al. Source attribution of poly- and perfluoroalkyl substances (PFASs) in surface waters from Rhode Island and the New York Metropolitan Area. *Environ Sci Technol Lett.* 2016;3:316–21.
  82. Tittlemier SA, Pepper K, Seymour C, Moisey J, Bronson R, Cao X-L, et al. Dietary exposure of Canadians to perfluorinated carboxylates and perfluorooctane sulfonate via consumption of meat, fish, fast foods, and food items prepared in their packaging. *J Agric Food Chem.* 2007;55:3203–10.
  83. Li M, von Stackelberg K, Rheinberger CM, Hammit JK, Krabbenhoft DP, Yin R, et al. Insights from mercury stable isotopes into factors affecting the internal body burden of methylmercury in frequent fish consumers. *Elem Sci Anth.* 2016;4:000103.
  84. Thurston GD, Spengler JD. A quantitative assessment of source contributions to inhalable particulate matter pollution in metropolitan Boston. *Atmos Environ.* 1967;1985:9–25.
  85. Yeung LW, Miyake Y, Taniyasu S, Wang Y, Yu H, So MK, et al. Perfluorinated compounds and total and extractable organic fluorine in human blood samples from China. *Environ Sci Technol.* 2008;42:8140–5.
  86. Miyake Y, Yamashita N, So MK, Rostkowski P, Taniyasu S, Lam PK, et al. Trace analysis of total fluorine in human blood using combustion ion chromatography for fluorine: a mass balance approach for the determination of known and unknown organofluorine compounds. *J Chromatogr A.* 2007;1154:214–21.
  87. Taves DR. Evidence that there are two forms of fluoride in human serum. *Nature.* 1968;217:1050.
  88. Hansen KJ, Clemen LA, Ellefson ME, Johnson HO. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. *Environ Sci Technol.* 2001;35:766–70.
  89. Grandjean P. Delayed discovery, dissemination, and decisions on intervention in environmental health: a case study on immunotoxicity of perfluorinated alkylated substances. *Environ Health.* 2018;17. <https://doi.org/10.1186/s12940-12018-10405-y>.
  90. Harris MH, Rifas-Shiman SL, Calafat AM, Ye X, Mora AM, Webster TF, et al. Predictors of per- and polyfluoroalkyl substance (PFAS) plasma concentrations in 6–10 year old American children. *Environ Sci Technol.* 2017;51:5193–204.
  91. Hurley S, Goldberg D, Wang M, Park JS, Petreas M, Bernstein L, et al. Time trends in per- and polyfluoroalkyl substances (PFASs) in California women: declining serum levels, 2011–5. *Environ Sci Technol.* 2018;52:277–87.
  92. Glynn A, Benskin J, Lignell S, Gyllenhammar I, Aune M, Cantillana T, et al. Temporal trends of perfluoroalkyl substances in pooled serum samples from first-time mothers in Uppsala 1997–2014. Report to the Swedish EPA; 2015.
  93. Eriksson U, Mueller JF, Toms LL, Hobson P, Karrman A. Temporal trends of PFASs, PFCAs and selected precursors in Australian serum from 2002 to 2013. *Environ Pollut.* 2017;220:168–77.
  94. Haug LS, Thomsen C, Becher GB. Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. *Environ Sci Technol.* 2009;43:2131–6.
  95. Yeung LW, Miyake Y, Taniyasu S, Wang Y, Yu H, So MK, et al. Perfluorinated compounds and total and extractable organic fluorine in human blood samples from China. *Environ Sci Technol.* 2008;42:8140–5.
  96. Mohsin M, Sarwar N, Ahmad S, Rasheed A, Ahmad F, Afzal A, et al. Maleic acid crosslinking of C-6 fluorocarbon as oil and water repellent finish on cellulosic fabrics. *J Clean Prod.* 2016;112:3525–30.
  97. Ritter SK. Fluorochemicals go short. *Chem Eng News Arch.* 2010;88:12–7.
  98. Bjerregaard-Olesen C, Bach CC, Long M, Ghisari M, Bossi R, Bech BH, et al. Time trends of perfluorinated alkyl acids in serum from Danish pregnant women 2008–2013. *Environ Int.* 2016;91:14–21.
  99. Kato K, Wong L-Y, Jia LT, Kuklennyk Z, Calafat AM. Trends in exposure to polyfluoroalkyl chemicals in the US population: 1999–2008. *Environ Sci Technol.* 2011;45:8037–45.
  100. Paul AG, Jones KC, Sweetman AJ. A first global production, emission, and environmental inventory for perfluorooctane sulfonate. *Environ Sci Technol.* 2009;43:386–92.
  101. Griffith FD, Long JE. Animal toxicity studies with ammonium perfluorooctanoate. *Am Ind Hyg Assoc J.* 1980;41:576–83.

102. Ubel FA, Sorenson SD, Roach DE. Health status of plant workers exposed to fluorochemicals—a preliminary report. *Am Ind Hyg Assoc J*. 1980;41:584–9.
103. Goldenthal EI, Jessup DC, Geil RG, Mehning JS. 90-day subacute rhesus monkey toxicity study no. 137-092. Available on USEPA Public Docket AR-226-0137. Mattawan, MI: International Research and Development Corp.; 1978.
104. Goldenthal EI, Jessup DC, Geil RG, Mehning JS. 90-day subacute rhesus monkey toxicity study (aborted) no. 137-087. Available on USEPA Public Docket AR-226-0138. Mattawan, MI: International Research and Development Corp.; 1978.
105. RIKER laboratories. Two year oral (diet) toxicity/carcinogenicity study of fluorochemical FM-3924 in rats. Available on USEPA Public Docket AR-226-0257. St. Paul, Minnesota: RIKER Laboratories, Inc./3M Company; 1983.
106. Sibinski LJ, Allen JL, Elrod SV. Two year oral (diet) toxicity—oncogenicity study of fluorocarbon FM-3924 in rats. Available on USEPA Public Docket AR-226-0262. St. Paul, MN; 1988.
107. Pathology Associates International. Pathology review of reported tumorigenesis in a two year study of FM-3924 in rats. Available on U.S. EPA public docket AR-226-0264. West Chester, Ohio; 1998.
108. McMichael AJ. Standardized mortality ratios and the “healthy worker effect”: Scratching beneath the surface. *J Occup Med*. 1976;18:165–8.
109. Gilliland FD. Fluorocarbons and human health: studies in an occupational cohort. Available on U.S. EPA Public Docket AR-226-0473. University of Minnesota; 1992.
110. Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. *J Occup Environ Med*. 1998;40:614–22.
111. Palmer CN, Hsu M-H, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor- $\alpha$  expression in human liver. *Mol Pharmacol*. 1998;53:14–22.
112. Barry V, Winqvist A, Steenland K. Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. *Environ Health Perspect*. 2013;121:1313.
113. Lopez-Espinosa M-J, Mondal D, Armstrong B, Bloom MS, Fletcher T. Thyroid function and perfluoroalkyl acids in children living near a chemical plant. *Environ Health Perspect*. 2012;120:1036.
114. Steenland K, Zhao L, Winqvist A, Parks C. Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. *Environ Health Perspect*. 2013;121:900.
115. Darrow LA, Stein CR, Steenland K. Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005–2010. *Environ Health Perspect*. 2013;121:1207.
116. Rappazzo K, Coffman E, Hines E. Exposure to perfluorinated alkyl substances and health outcomes in children: a systematic review of the epidemiologic literature. *Int J Environ Res Public Health*. 2017;14:691.
117. Grandjean P, Andersen E, Budtz-Jørgensen E, et al. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. *JAMA*. 2012;307:391–7.
118. Klaunig JE, Shinohara M, Iwai H, Chengelis CP, Kirkpatrick JB, Wang Z, et al. Evaluation of the chronic toxicity and carcinogenicity of perfluorohexanoic acid (PFHxA) in Sprague–Dawley rats. *Toxicol Pathol*. 2014;43:209–20.
119. Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid production plant. *J Occup Med*. 1993;35:950–4.
120. Raleigh KK, Alexander BH, Olsen GW, Ramachandran G, Morey SZ, Church TR, et al. Mortality and cancer incidence in ammonium perfluorooctanoate production workers. *Occup Environ Med*. 2014;71:500–6.
121. Vieira VM, Hoffman K, Shin HM, Weinberg JM, Webster TF, Fletcher T. Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. *Environ Health Perspect*. 2013;121:318–23.
122. Eriksen KT, Sorensen M, McLaughlin JK, Lipworth L, Tjonneland A, Overvad K, et al. Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. *J Natl Cancer Inst*. 2009;101:605–9.
123. DeWitt JC, Peden-Adams MM, Keller JM, Germolec DR. Immunotoxicity of perfluorinated compounds: recent developments. *Toxicol Pathol*. 2012;40:300–11.
124. Stein CR, McGovern KJ, Pajak AM, Maglione PJ, Wolff MS. Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12–19 y: National Health and Nutrition Examination Survey. *Pediatr Res*. 2016;79:348–57.
125. Granum B, Haug LS, Namork E, Stolevik SB, Thomsen C, Aaberge IS, et al. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. *J Immunotoxicol*. 2013;10:373–9.
126. Stein CR, Ge YC, Wolff MS, Ye XY, Calafat AM, Kraus T, et al. Perfluoroalkyl substance serum concentrations and immune response to FluMist vaccination among healthy adults. *Environ Res*. 2016;149:171–8.
127. Looker C, Luster MI, Calafat AM, Johnson VJ, Burleson GR, Burleson FG, et al. Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. *Toxicol Sci*. 2014;138:76–88.
128. Dong G-H, Tung K-Y, Tsai C-H, Liu M-M, Wang D, Liu W, et al. Serum polyfluoroalkyl concentrations, asthma outcomes, and immunological markers in a case-control study of Taiwanese children. *Environ Health Perspect*. 2013;121:507–13.
129. Buser MC, Scinicariello F. Perfluoroalkyl substances and food allergies in adolescents. *Environ Int*. 2016;88:74–9.
130. Gilliland FD, Mandel JS. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. *Am J Ind Med*. 1996;29:560–8.
131. Liu HS, Wen LL, Chu PL, Lin CY. Association among total serum isomers of perfluorinated chemicals, glucose homeostasis, lipid profiles, serum protein and metabolic syndrome in adults: NHANES, 2013–2014. *Environ Pollut*. 2018;232:73–9.
132. Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). *Environ Health Perspect*. 2010;118:1100–8.
133. Cardenas A, Gold DR, Hauser R, Kleinman KP, Hivert MF, Calafat AM, et al. Plasma concentrations of per- and polyfluoroalkyl substances at baseline and associations with glycemic indicators and diabetes incidence among high-risk adults in the diabetes prevention program trial. *Environ Health Perspect*. 2017;125:107001.
134. Liu G, Dhana K, Furtado JD, Rood J, Zong G, Liang L, et al. Perfluoroalkyl substances and changes in body weight and resting metabolic rate in response to weight-loss diets: a prospective study. *PLoS Med*. 2018;15:e1002502.
135. Frisbee SJ, Shankar A, Knox SS, Steenland K, Savitz DA, Fletcher T, et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. *Arch Pediatr Adolesc Med*. 2010;164:860–9.
136. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. *Environ Health Perspect*. 2010;118:197–202.



137. Maisonet M, Näyhä S, Lawlor DA, Marcus M. Prenatal exposures to perfluoroalkyl acids and serum lipids at ages 7 and 15 in females. *Environ Int.* 2015;82:49–60.
138. Lin CY, Chen PC, Lin YC, Lin LY. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. *Diabetes Care.* 2009;32:702–7.
139. Zhang C, Sundaram R, Maisog J, Calafat AM, Barr DB, Buck Louis GM. A prospective study of prepregnancy serum concentrations of perfluorochemicals and the risk of gestational diabetes. *Fertil Steril.* 2015;103:184–9.
140. Matilla-Santander N, Valvi D, Lopez-Espinosa MJ, Manzano-Salgado CB, Ballester F, Ibarluzea J, et al. Exposure to perfluoroalkyl substances and metabolic outcomes in pregnant women: evidence from the Spanish INMA Birth Cohorts. *Environ Health Perspect.* 2017;125:117004.
141. Min JY, Lee KJ, Park JB, Min KB. Perfluorooctanoic acid exposure is associated with elevated homocysteine and hypertension in US adults. *Occup Environ Med.* 2012;69:658–62.
142. Geiger SD, Xiao J, Shankar A. No association between perfluoroalkyl chemicals and hypertension in children. *Integr Blood Press Control.* 2014;7:1–7.
143. Conway B, Costacou T. Perfluoroalkyl acids and stroke risk in persons with and without diabetes: a salutatory effect of high oxygen carrying capacity environmental contaminants. *Circulation.* 2018;133:AP061.
144. Steenland K, Zhao L, Winquist A. A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). *Occup Environ Med.* 2015;72:373–80.
145. Lin CY, Lin LY, Wen TW, Lien GW, Chien KL, Hsu SHJ, et al. Association between levels of serum perfluorooctane sulfate and carotid artery intima-media thickness in adolescents and young adults. *Int J Cardiol.* 2013;168:3309–16.
146. Koshy TT, Attina TM, Ghassabian A, Gilbert J, Burdine LK, Marmor M, et al. Serum perfluoroalkyl substances and cardiometabolic consequences in adolescents exposed to the World Trade Center disaster and a matched comparison group. *Environ Int.* 2017;109:128–35.
147. Olsen GW, Ehresman DJ, Buehrer BD, Gibson BA, Butenhoff JL, Zobel LR. Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. *J Occup Environ Med/Am Coll Occup Environ Med.* 2012;54:974–83.
148. Lin CY, Lin LY, Chiang CK, Wang WJ, Su YN, Hung KY, et al. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. *Am J Gastroenterol.* 2010;105:1354–63.
149. Wang X, Li B, Zhao W-D, Liu Y-J, Shang D-S, Fang W-G, et al. Perfluorooctane sulfonate triggers tight junction “opening” in brain endothelial cells via phosphatidylinositol 3-kinase. *Biochem Biophys Res Commun.* 2011;410:258–63.
150. Johansson N, Fredriksson A, Eriksson P. Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. *Neurotoxicology.* 2008;29:160–9.
151. Liew Z, Goudarzi H, Oulhote Y. Developmental exposures to perfluoroalkyl substances (PFASs): an update of associated health outcomes. *Curr Environ Health Rep.* 2018;5:1–19.
152. Yeung LW, Mabury SA. Are humans exposed to increasing amounts of unidentified organofluorine? *Environ Chem.* 2016;13:102–10.
153. Gomis MI, Vestergren R, Nilsson H, Cousins IT. Contribution of direct and indirect exposure to human serum concentrations of perfluorooctanoic acid in an occupationally exposed group of Ski Waxers. *Environ Sci Technol.* 2016;50:7037–46.
154. Rotander A, Karrman A, Toms LM, Kay M, Mueller JF, Gomez Ramos MJ. Novel fluorinated surfactants tentatively identified in firefighters using liquid chromatography quadrupole time-of-flight tandem mass spectrometry and a case-control approach. *Environ Sci Technol.* 2015;49:2434–42.
155. Olsen GW, Chang S-C, Noker PE, Gorman GS, Ehresman DJ, Lieder PH, et al. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans. *Toxicology.* 2009;256:65–74.
156. Fujii Y, Niisoe T, Harada KH, Uemoto S, Ogura Y, Takenaka K, et al. Toxicokinetics of perfluoroalkyl carboxylic acids with different carbon chain lengths in mice and humans. *J Occup Health.* 2015;57:1–12.
157. Ritter SK. Fluorochemicals go short. *Chem Eng News.* 2010;88:12–7.
158. Butt CM, Muir DC, Mabury SA. Biotransformation pathways of fluorotelomer-based polyfluoroalkyl substances: a review. *Environ Toxicol Chem/SETAC.* 2014;33:243–67.
159. Strynar M, Dagnino S, McMahan R, Liang S, Lindstrom A, Andersen E, et al. Identification of novel perfluoroalkyl ether carboxylic acids (PFECAs) and sulfonic acids (PFESAs) in natural waters using accurate mass time-of-flight mass spectrometry (TOFMS). *Environ Sci Technol.* 2015;49:11622–30.
160. Wang Z, Cousins IT, Scheringer M, Hungerbühler K. Fluorinated alternatives to long-chain perfluoroalkyl carboxylic acids (PFCAs), perfluoroalkane sulfonic acids (PFASs) and their potential precursors. *Environ Int.* 2013;60:242–8.
161. Blum A, Balan SA, Scheringer M, Trier X, Goldenman G, Cousins IT, et al. The Madrid statement on poly-and perfluoroalkyl substances (PFASs). *Environ Health Perspect.* 2015;123:A107.
162. Boxer E, Chaves N, Niwa Y. Northeastern SSEHRI PFAS contamination site tracker; 2018.
163. Tian Z, Kim S-K, Shoeib M, Oh J-E, Park J-E. Human exposure to per- and polyfluoroalkyl substances (PFASs) via house dust in Korea: implication to exposure pathway. *Sci Total Environ.* 2016;553:266–75.
164. Shan G, Wang Z, Zhou L, Du P, Luo X, Wu Q, et al. Impacts of daily intakes on the isomeric profiles of perfluoroalkyl substances (PFASs) in human serum. *Environ Int.* 2016;89-90:62–70.
165. Gebbink WA, Berger U, Cousins IT. Estimating human exposure to PFOS isomers and PFCA homologues: the relative importance of direct and indirect (precursor) exposure. *Environ Int.* 2015;74:160–9.
166. Wang, Z., J. M. Boucher, M. Scheringer, I. T. Cousins, and K. Hungerbühler (2017), *Toward a Comprehensive Global Emission Inventory of C4–C10 Perfluoroalkanesulfonic Acids (PFASs) and Related Precursors: Focus on the Life Cycle of C8-Based Products and Ongoing Industrial Transition*, *Environmental Science & Technology*, 51(8), 4482–4493.

Supplemental material

**A Review of the Pathways of Human Exposure to Poly- and Perfluoroalkyl Substances (PFASs) and Present Understanding of Health Effects**

Elsie M. Sunderland, Xindi C. Hu, Clifton Dassuncao, Andrea K. Tokranov, Charlotte C. Wagner, Joseph G. Allen

Table S1 Studies of PFASs and immunity, infection, and asthma related outcomes.

Paper	Study design	Country	Year of study	Representativeness	Demographics	N	Exposure level, ng/mL (mean or median)	Outcome	Summary of results	Selected effect estimates (β)
1 Anderson-Mahoney et al. (2008) <sup>1</sup>	cross-sectional	US	2003	environmental, occupational	C8 Health Project	566	residence history	asthma	Position associations between living in PFOA contaminated area and asthma prevalence	1.82 (1.47-3.21)
2 Fletcher et al. (2009) <sup>2</sup>	cross-sectional	US	2005-2006	environmental	C8 Health Project	56315	much higher than normal background	immune markers	Negative associations between immunoglobulins and PFOA	/
3 Fei et al. (2010) <sup>3</sup>	cohort	Denmark	1996-2002	environmental	mother-child pair	1400	PFOA 5.6; PFOS 35.3	infection	No significant associations between hospitalizations due to infections and prenatal exposure to PFOA and PFOS	IRR for PFOS 1.00 (0.91, 1.09); PFOA 0.96 (0.87, 1.06)
4 Wang et al. (2011) <sup>4</sup>	cohort	Taiwan	2004	environmental	mother-child pair	244	PFOA 1.7; PFOS 5.5; PFNA 2.3; PFHxS 0.035	immune markers	Prenatal PFOA and PFOS exposures were positively correlated with cord blood IgE levels, but were not significantly associated with atopic dermatitis.	per ln-unit: β=0.134 KU/l, p=0.047 for PFOA; β=0.161 KU/l, p=0.017 for PFOS
5 Grandjean et al. (2012) <sup>5</sup>	cohort	Faroe Islands	1997-2000	environmental	mother-child pair	587	maternal serum PFOA 3.20; PFOS 27.3; PFHxS 4.41; PFNA 0.60; PFDA 0.28; child serum PFOA 4.06; PFOS 16.7; PFHxS 0.53; PFNA	vaccine antibody	Negative associations between antibody levels and latent factor (PFOA, PFOS and PFHxS)	SEM: 2-fold greater concentration of major PFCs in child serum associates with -49% in the overall antibody concentration

								1.00; PFDA 0.28			
6	Okada et al. (2012) <sup>6</sup>	cohort	Japan	2002-2005	environmental	mother-child pair	343	PFOS 5.2; PFOA 1.3	immune markers, infection, allergy	Negative associations with IgE level and maternal PFOA levels among female infants, no relationship was found between maternal PFOS and PFOA levels and infant allergies and infectious diseases at age in 18 months	In female infants, when log10-transformed maternal PFOA levels changed from 0.3ng/mL to 0.7ng/mL, log10-transformed cord blood IgE levels greatly decreased by 0.86IU/mL
7	Dong et al. (2013) <sup>7</sup>	cross-sectional	Taiwan	2009-2010	environmental	children	456	PFOS 33.9 in asthmatics and 28.9 in controls, other PFASs include PFOA, PFBS, PFDA, PFDoA, PFHpA, PFHxA, PFHxS, PFNA, and PFTA	immune markers, asthma	Among children with asthma, all but one of the PFASs evaluated were positively associated with at least two of the three immunological biomarkers. Crude and adjusted ORs for asthma in association with the highest versus low-est quartile of exposure were significantly elevated for all PFASs except for PFHxA and PFTA.	Adjusted odds ratios for asthma among those with the highest versus lowest quartile of PFAS exposure ranged from 1.81 (95% CI: 1.02, 3.23) for the PFDoA to 4.05 (95% CI: 2.21, 7.42) for PFOA.
8	Granum et al. (2013) <sup>8</sup>	cohort	Norway	2007-2008	environmental	mother-child pair	99	PFOA 1.1; PFNA 0.3; PFHxS 0.3; PFOS 5.5	vaccine antibody, immune markers, asthma, infection, allergy	Negative association between anti-rubella antibodies and four PFAS (PFNA>PFOA>PFHxS>PFOS). Positive association between maternal PFOA and PFNA and the number of episodes of common cold for the children, and between PFOA and PFHxS and the number of episodes of gastroenteritis. No associations between maternal PFAS and allergy or asthma.	Rubella antibody and PFOA $\beta$ =-0.40 (-0.64, -0.17); PFNA $\beta$ =-1.38 (-2.35, -0.40); PFHxS $\beta$ =-0.38 (-0.55, -0.11); PFOS $\beta$ = -0.08 (-0.14, -0.02)
9	Steenland et al. (2013) <sup>9</sup>	cohort	US	2005-2006	environmental	C8 Health Project	28541	PFOA 24	autoimmune diseases	Positive association between ulcerative colitis and cumulative	Adjusted rate ratios of ulcerative colitis by quartile of PFOA

										PFOA exposure, non significant for all others	exposure of 1.00 (referent), 1.76 (95% CI: 1.04, 2.99), 2.63 (95% CI: 1.56, 4.43), and 2.86 (95% CI: 1.65, 4.96) (ptrend < 0.0001)
10	Steenland et al. (2013) <sup>9</sup>	cohort	US	2005-2006	occupational	C8 Health Project	3713	PFOA 113	autoimmune diseases	Positive association between ulcerative colitis and cumulative PFOA exposure	A prospective analysis of ulcerative colitis diagnosed after the baseline 2005–2006 survey (n= 29 cases) suggested a positive but non-monotonic trend (ptrend = 0.21)
11	Looker et al. (2014) <sup>10</sup>	cross-sectional	US	2010	environmental	C8 Health Project	403	PFOA 31.5; PFOS 9.2	vaccine antibody, infection	Negative association between influenza vaccine antibody and PFOA, non significant for infections with PFOA and non significant for PFOS with any endpoints examined	Highest quartile of PFOA $\beta$ =−0.22 (95% CI: −0.43, −0.01)
12	Humblet et al. (2014) <sup>11</sup>	cross-sectional	US	1999-2000, 2003-2008	environmental	teenagers in NHANES	1877	PFOA 4; PFOS 16.8	asthma, infection	Positive association between PFOA and asthma diagnosis. Negative association between PFOS and asthma and wheezing. Non-significant for other PFASs and other outcomes	PFOA and asthma [odds ratio = 1.18; 95% CI: 1.01, 1.39 for a doubling in PFOA]. PFOS and asthma and wheezing (OR = 0.88; 95% CI: 0.74, 1.04, and OR = 0.83; 95% CI: 0.67, 1.02, respectively).
13	Smit et al. (2015) <sup>12</sup>	cross-sectional	Greenland, Ukraine	2002-2004	environmental	mother-child pair	1024	PFOS 4.88 (Ukraine) 20.6 (Greenland)	asthma, infection	Not consistent between PFAS and asthma, eczema, and wheeze among the two populations	Among Ukrain children, PC5 score, dominated by PFOA, was inversely associated with current wheeze (OR 0.64, 0.41-0.99)
14	Steenland et al. (2015) <sup>13</sup>	cohort	US	2005	occupational	C8 Health Project	3713	PFOA 113	infection	Positive association for PFOA and ulcerative colitis (10-year lag); Positive association for PFOA and rheumatoid arthritis (no lag); Negative association between PFOA and asthma	Ulcerative colitis (10-year lag) RRs=1.00, 3.00, 3.26, 6.57, p for trend=0.05. Rheumatoid arthritis (no lag) RRs=1.00, 2.11, 4.08, 4.45, p for trend=0.04.
15	Buser et	cross-	US	2005-	environmental	NHANES	1338	2005–2006,	immune	Positive associations for	PFOA, PFHxS and self-

	al. (2016) <sup>14</sup>	section al		2006, 2007- 2010				PFOA, PFNA, PFOS and PFHxS were 3.59, 0.93, 14.98, and 2.09. 2007- 2010, PFOA, PFNA, PFOS and PFHxS were 3.27, 1.13, 8.74 , and 2.19	markers, allergy	PFOA, PFOS and PFHxS and self-reported food allergies. Negative association for PFNA and food IgE	reported food allergies, OR = 9.09, 95% CI: 3.32, 24.90 and OR = 3.06, 95% CI: 1.35, 6.93, respectively. Highest PFNA quartile and food sensitization OR = 0.51, 95% CI: 0.28, 0.92) compared to lowest quartile
16	Dalsager et al. (2016) <sup>15</sup>	cohort	Denmar k	2010- 2012	environmental	mother-child pair	649	PFOS, PFOA, PFHxS, PFNA, PFDA: 8.07, 1.68, 0.32, 0.70, 0.27	infection	Positive associations for PFOS and PFOA and fever	PFOS high tertile compared to the low tertile was associated with increased proportion of days with fever (IRR: 1.65 (95% CI: 1.24, 2.18), P- trend<0.001) and an increased odds of experiencing days with fever above the median (OR: 2.35 (95% CI: 1.31, 4.11)). PFOA (OR: 1.97 (95% CI: 1.07, 3.62)
17	Stein et al. (2016a) <sup>16</sup>	cohort	US	2010- 2011	environmental	healthy adults	78	PFOS, PFOA, PFHxS, PFNA: 5.22, 2.28, 1.1, 0.77	vaccine antibody, immune markers	Positive association for PFAS and seroconversion. Non significant for PFAS and baseline cytokine, chemokine or mucosal IgA concentration, or changes between baseline and post- vaccine	Children with higher PFOS concentration were less likely to be sensitized to any allergen (odds ratio (OR): 0.74; 95% CI: 0.58, 0.95).
18	Stein et al. (2016b) <sup>17</sup>	cross- section al	US	1999- 2000, 2003- 2004, 2005- 2006	environmental	NHANES	3022	0.76 for PFNA, 20.8 for PFOS	vaccine antibody, allergy, asthma	Negative association for PFOS and rubella and mumps antibody concentrations. Non- significant for PFASs and allergic conditions including asthma	PFOS concentration among seropositive children was associated with a 13.3% (95% CI: - 19.9, -6.2) decrease in rubella antibody concentration and a 5.9% decrease in mumps antibody concentration (95% CI: -9.9, -1.6).
19	Zhu et al.	case-	Taiwan	2009-	environmental	children	456	PFOS 33.39	immune	Positive association for	Among males, adjusted

(2016) <sup>18</sup>	control		2010					for non-asthmatic children, 37.28 for asthmatic children	markers	PFASs and asthma, especially among males. Non-significant for PFASs and T(H)2 cytokines among females	odds ratios for asthma among those with the highest versus lowest quartile of PFAAs exposure ranged from 2.59 (95% CI: 1.14, 5.87) for the PFBS to 4.38 (95% CI: 2.02, 9.50) for PFOS
20	Goudarzi et al. (2017) <sup>19</sup>	cohort	Japan	2003-2009	environmental	mother-child pair	1558	PFOS 4.92, PFOA 2.01, PFUnDA 1.43, PFNA 1.18	infection	Positive association for PFOS and PFHxS and total infectious diseases, non-significant for other PFAAs	PFOS levels in the highest quartile were associated with increased ORs of total infectious diseases (Q4 vs. Q1 OR: 1.61; 95% CI: 1.18, 2.21; p for trend = 0.008) in all children. In addition, PFHxS was associated with a higher risk of total infectious diseases only among girls (Q4 vs. Q1 OR: 1.55, 95% CI: 0.976, 2.45; p for trend = 0.045).
21	Qin et al. (2017) <sup>20</sup>	case-control	China	2009-2010	environmental	children	300	PFOA 1.02 in cases and 0.50 in controls	asthma	Positive association for PFAS and asthma. Negative association for PFAS and lung function among children with asthma. Non-significant for PFAS and lung function among children without asthma	PFASs and asthma, with adjusted ORs ranging from 0.99 (95% confidence interval [CI]: 0.80-1.21) to 2.76 (95% CI: 1.82-4.17). Adjusted coefficients between lung function and PFASs exposure ranged from -0.055 (95%CI: -0.100 to -0.010) for FVC and PFOS to -0.223 (95%CI: -0.400 to -0.045) for FEF25-75 and PFOA.
22	Timmermann et al. (2017) <sup>21</sup>	cohort	Faroe Islands	1997-2000	environmental	mother-child pair	559	PFOA 9.3	Immune markers, asthma, allergy	Positive association for five PFASs at age 5 years and asthma at ages 5 and 13. The associations were reversed among MMR-vaccinated children. Non-significant for	Among MMR-unvaccinated children, a doubling in PFASs at age 5 was significantly associated with 9-75-fold higher odds of atopic asthma at age 5, and a doubling of PFNA

23	Zhou et al. (2017a) <sup>22</sup>	case-control	Taiwan	2009-2010	environmental	children	456	PFOS among children with asthma 36.9(boy) 28.2(girl), without asthma 29.9(boy) 28.8(girl)	asthma	asthma or allergic diseases	was associated with 7-fold higher odds of atopic asthma at age 13
										Negative association between urinary CC16 and PFOS, PFOA, PFDA and PFNA, and especially among males	PFOS (beta = -0.003, 95% confidence interval [CI]: -0.004, -0.002), PFOA (beta = -0.045, 95% CI: -0.086, -0.004), and PFHxA (beta = -0.310, 95% CI: -0.455, -0.165) among asthmatic boys, and PFDA (beta = -0.126, 95%CI: -0.241, -0.012) and PFNA (beta = -0.329, 95% CI: -0.526, -0.132) among non-asthmatic boys. Among girls, PFDA (beta = -0.088, 95% CI: -0.172, -0.004), was the only PFAS significantly associated with CC16
24	Zhou et al. (2017b) <sup>23</sup>	case-control	Taiwan	2009-2010	environmental	children	456	PFOS among children with asthma 33.94, without asthma 28.91	asthma		OR for asthma ranging from 1.25 for PFOS (95% CI: 0.90, 1.72) to 4.01 for PFDA (95% CI: 1.46, 11.06) among boys and 1.25 for PFOS (95% CI: 0.84, 1.86) to 4.16 for PFNA (95% CI: 1.36, 12.73) among girls
										Among asthmatics, positive association between PFASs and estradiol levels and negative association between PFASs and testosterone levels.	
25	Chen et al. (2018) <sup>24</sup>	cohort	China	2012-2015	environmental	mother-child pair	1056	PFOS 2.5; PFOA 7.0; PFNA 0.4; PFDA 0.4; PFUnDA 0.4; PFDoDA 0.1; PFHxS 0.2; PFBS 0.05	infection		In female children, PFOA and AD risk (AOR 2.07, 95% CI 1.13-3.80). PFNA 2.22 (1.07-4.58). The highest PFOA quartile was significantly associated with AD (2.52, 1.12-5.68) compared with the lowest quartile. The highest quartile of PFNA, PFDA and PFHxS were associated with AD with AOR (95% CI) being 2.14 (0.97-4.74), 2.14 (1.00-4.57), and 2.30 (1.03-
										Positive associations for PFOA, PFDA, PFDoA and atopic dermatitis (AD) among female, almost positive association for PFNA and AD among female, non-significant for male	

											5.15), respectively. The second quartile of PFDoA was associated with a 3.2-fold increase in AD risk (3.24, 1.44-7.27).
26	Impinen et al. (2018) <sup>25</sup>	cohort	Norway	1992-1993, 1994-1995, 2002-2003	environmental	mother-child pair	641	PFOA 1.6; PFOS 5.2; PFOSA 0.4; PFHxS 0.2; PFNA 0.2; PFUnDA 0.1	asthma, infection, allergy	Positive associations for PFASs and reported airways infections. Non-significant ofr allergy and asthma	Common colds by two years with PFUnDA (beta = 0.11 (0.08-0.14)) and LATIs from 0 to 10 years of age with PFOS (beta = 0.50 (0.42-0.57)), PFOA (beta = 0.28 (0.22-0.35)), PFOSA (beta = 0.10 (0.06-0.14)), PFNA (beta = 0.09 (0.03-0.14)) and PFUnDA (beta = 0.18 (0.13-0.23)) concentrations

#### References:

1. Anderson-Mahoney P, Kotlerman J, Takhar H, Gray D, Dahlgren J Self-reported health effects among community residents exposed to perfluorooctanoate. *NEW SOLUTIONS: A Journal of Environmental and Occupational Health Policy* 2008; 18: 129-143.
2. Fletcher T SK, Savitz D. Status Report: PFOA and immune biomarkers in adults exposed to PFOA in drinking water in the mid Ohio valley. In: *C8 Science Panel Web site*, 2009.
3. Fei C, McLaughlin JK, Lipworth L, Olsen J Prenatal exposure to PFOA and PFOS and risk of hospitalization for infectious diseases in early childhood. *Environmental research* 2010; 110: 773-777.
4. Wang IJ, Hsieh W-S, Chen C-Y, Fletcher T, Lien G-W, Chiang H-L *et al* The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. *Environmental research* 2011; 111: 785-791.
5. Grandjean P, Andersen EW, Budtz-Jorgensen E, Nielsen F, Molbak K, Weihe P *et al* Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. *Jama* 2012; 307: 391-397.
6. Okada E, Sasaki S, Saijo Y, Washino N, Miyashita C, Kobayashi S *et al* Prenatal exposure to perfluorinated chemicals and relationship with allergies and infectious diseases in infants. *Environmental research* 2012; 112: 118-125.
7. Dong G-H, Tung K-Y, Tsai C-H, Liu M-M, Wang D, Liu W *et al* Serum Polyfluoroalkyl Concentrations, Asthma Outcomes, and Immunological Markers in a Case-Control Study of Taiwanese Children. *Environmental health perspectives* 2013; 121: 507-513.



8. Granum B, Haug LS, Namork E, Stolevik SB, Thomsen C, Aaberge IS *et al* Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. *Journal of immunotoxicology* 2013; 10: 373-379.
9. Steenland K, Zhao L, Winquist A, Parks C Ulcerative Colitis and Perfluorooctanoic Acid (PFOA) in a Highly Exposed Population of Community Residents and Workers in the Mid-Ohio Valley. *Environmental health perspectives* 2013; 121: 900-905.
10. Looker C, Luster MI, Calafat AM, Johnson VJ, Burlison GR, Burlison FG *et al* Influenza Vaccine Response in Adults Exposed to Perfluorooctanoate and Perfluorooctanesulfonate. *Toxicological Sciences* 2014; 138: 76-88.
11. Humblet O, Diaz-Ramirez LG, Balmes JR, Pinney SM, Hiatt RA Perfluoroalkyl chemicals and asthma among children 12-19 years of age: NHANES (1999-2008). *Environmental health perspectives* 2014; 122: 1129-1133.
12. Smit LAM, Lenters V, Hoyer BB, Lindh CH, Pedersen HS, Liermontova I *et al* Prenatal exposure to environmental chemical contaminants and asthma and eczema in school-age children. *Allergy (Oxford)* 2015; 70: 653-660.
13. Steenland K, Zhao LP, Winquist A A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). *Occupational and environmental medicine* 2015; 72: 373-380.
14. Buser MC, Scinicariello F Perfluoroalkyl substances and food allergies in adolescents. *Environment international* 2016; 88: 74-79.
15. Dalsager L, Christensen N, Husby S, Kyhl H, Nielsen F, Host A *et al* Association between prenatal exposure to perfluorinated compounds and symptoms of infections at age 1-4years among 359 children in the Odense Child Cohort. *Environment international* 2016; 96: 58-64.
16. Stein CR, Ge YC, Wolff MS, Ye XY, Calafat AM, Kraus T *et al* Perfluoroalkyl substance serum concentrations and immune response to FluMist vaccination among healthy adults. *Environmental research* 2016; 149: 171-178.
17. Stein CR, McGovern KJ, Pajak AM, Maglione PJ, Wolff MS Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12-19 y: National Health and Nutrition Examination Survey. *Pediatric research* 2016; 79: 348-357.
18. Zhu Y, Qin X-D, Zeng X-W, Paul G, Morawska L, Su M-W *et al* Associations of serum perfluoroalkyl acid levels with T-helper cell-specific cytokines in children: By gender and asthma status. *Science of the Total Environment* 2016; 559: 166-173.
19. Goudarzi H, Miyashita C, Okada E, Kashino I, Chen C-J, Ito S *et al* Prenatal exposure to perfluoroalkyl acids and prevalence of infectious diseases up to 4 years of age. *Environment international* 2017; 104: 132-138.
20. Qin XD, Qian ZM, Dharmage SC, Perret J, Geiger SD, Rigdon SE *et al* Association of perfluoroalkyl substances exposure with impaired lung function in children. *Environmental research* 2017; 155: 15-21.

21. Timmermann CAG, Budtz-Jorgensen E, Jensen TK, Osuna CE, Petersen MS, Steuerwald U *et al* Association between perfluoroalkyl substance exposure and asthma and allergic disease in children as modified by MMR vaccination. *Journal of immunotoxicology* 2017; 14: 39-49.
22. Zhou Y, Bao WW, Qian ZM, Dee Geiger S, Parrish KL, Yang BY *et al* Perfluoroalkyl substance exposure and urine CC16 levels among asthmatics: A case-control study of children. *Environmental research* 2017; 159: 158-163.
23. Zhou Y, Hu L-W, Qian Z, Geiger SD, Parrish KL, Dharmage SC *et al* Interaction effects of polyfluoroalkyl substances and sex steroid hormones on asthma among children. *Scientific Reports* 2017; 7: 899.
24. Chen Q, Huang R, Hua L, Guo YF, Huang LS, Zhao YJ *et al* Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study. *Environ Health* 2018; 17: 12.
25. Impinen A, Nygaard UC, Carlsen KCL, Mowinckel P, Carlsen KH, Haug LS *et al* Prenatal exposure to perfluoroalkyl substances (PFASs) associated with respiratory tract infections but not allergy- and asthma-related health outcomes in childhood. *Environmental research* 2018; 160: 518-523.